US20090029967A1 - Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders - Google Patents
Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders Download PDFInfo
- Publication number
- US20090029967A1 US20090029967A1 US12/181,736 US18173608A US2009029967A1 US 20090029967 A1 US20090029967 A1 US 20090029967A1 US 18173608 A US18173608 A US 18173608A US 2009029967 A1 US2009029967 A1 US 2009029967A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- alkoxy
- phenyl
- group
- adenosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 title claims abstract description 58
- 208000027776 Extrapyramidal disease Diseases 0.000 title claims abstract description 40
- 238000011282 treatment Methods 0.000 title claims abstract description 27
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 title claims abstract 9
- 208000016285 Movement disease Diseases 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 33
- 208000014094 Dystonic disease Diseases 0.000 claims abstract description 24
- 208000005793 Restless legs syndrome Diseases 0.000 claims abstract description 24
- 208000010118 dystonia Diseases 0.000 claims abstract description 24
- 230000033001 locomotion Effects 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 230000000737 periodic effect Effects 0.000 claims abstract description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 147
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 112
- 229910052739 hydrogen Inorganic materials 0.000 claims description 74
- 239000001257 hydrogen Substances 0.000 claims description 58
- 150000001875 compounds Chemical class 0.000 claims description 50
- 125000001424 substituent group Chemical group 0.000 claims description 43
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 41
- -1 1-thienyl Chemical group 0.000 claims description 38
- 229910052736 halogen Inorganic materials 0.000 claims description 35
- 150000002367 halogens Chemical class 0.000 claims description 35
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 33
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 32
- 239000000164 antipsychotic agent Substances 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 239000001961 anticonvulsive agent Substances 0.000 claims description 22
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 22
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims description 16
- 230000001773 anti-convulsant effect Effects 0.000 claims description 16
- 229960003965 antiepileptics Drugs 0.000 claims description 16
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 14
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 13
- 229910052744 lithium Inorganic materials 0.000 claims description 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 229960003878 haloperidol Drugs 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 10
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 10
- 229960005305 adenosine Drugs 0.000 claims description 10
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 10
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 229940049706 benzodiazepine Drugs 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 9
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 8
- 229960000423 loxapine Drugs 0.000 claims description 8
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims description 8
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 5
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 5
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 5
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 5
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 5
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims description 4
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 4
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 4
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 claims description 4
- 229960000911 benserazide Drugs 0.000 claims description 4
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 4
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 4
- 229960001076 chlorpromazine Drugs 0.000 claims description 4
- 229960004170 clozapine Drugs 0.000 claims description 4
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 4
- 229960004502 levodopa Drugs 0.000 claims description 4
- 229960005017 olanzapine Drugs 0.000 claims description 4
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 4
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 claims description 4
- 229960003111 prochlorperazine Drugs 0.000 claims description 4
- 229960004431 quetiapine Drugs 0.000 claims description 4
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 4
- 229960001534 risperidone Drugs 0.000 claims description 4
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 4
- 229960005013 tiotixene Drugs 0.000 claims description 4
- 229960000607 ziprasidone Drugs 0.000 claims description 4
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 4
- 229960000623 carbamazepine Drugs 0.000 claims description 3
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 3
- 229960003920 cocaine Drugs 0.000 claims description 3
- 239000002464 receptor antagonist Substances 0.000 claims description 3
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 2
- 229960000836 amitriptyline Drugs 0.000 claims description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003914 desipramine Drugs 0.000 claims description 2
- 229960005426 doxepin Drugs 0.000 claims description 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 2
- 229960002870 gabapentin Drugs 0.000 claims description 2
- 229960000762 perphenazine Drugs 0.000 claims description 2
- 229960002601 protriptyline Drugs 0.000 claims description 2
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002431 trimipramine Drugs 0.000 claims description 2
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 208000016570 early-onset generalized limb-onset dystonia Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 13
- 0 *C1=NN2C(N)=NC3=C(C=NN3C[Y]C)C2=N1 Chemical compound *C1=NN2C(N)=NC3=C(C=NN3C[Y]C)C2=N1 0.000 description 34
- VQKFNUFAXTZWDK-UHFFFAOYSA-N CC1=CC=CO1 Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 29
- 125000000217 alkyl group Chemical group 0.000 description 23
- 125000003118 aryl group Chemical group 0.000 description 21
- 125000001072 heteroaryl group Chemical group 0.000 description 13
- 239000005557 antagonist Substances 0.000 description 12
- 125000005843 halogen group Chemical group 0.000 description 12
- 239000013024 dilution buffer Substances 0.000 description 10
- 241000282693 Cercopithecidae Species 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 229960001078 lithium Drugs 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- KORDZSMOYNFCQG-UHFFFAOYSA-N CN1CCN(C2=CC=C(F)C=C2F)CC1 Chemical compound CN1CCN(C2=CC=C(F)C=C2F)CC1 KORDZSMOYNFCQG-UHFFFAOYSA-N 0.000 description 8
- 229940126062 Compound A Drugs 0.000 description 8
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 8
- 125000000623 heterocyclic group Chemical group 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229940125681 anticonvulsant agent Drugs 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 5
- 206010001540 Akathisia Diseases 0.000 description 5
- KYQKBQOYLXORKX-UHFFFAOYSA-N COCCOC1=CC=C(N2CCN(C)CC2)C(F)=C1 Chemical compound COCCOC1=CC=C(N2CCN(C)CC2)C(F)=C1 KYQKBQOYLXORKX-UHFFFAOYSA-N 0.000 description 5
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 5
- 229940005529 antipsychotics Drugs 0.000 description 5
- 150000001557 benzodiazepines Chemical class 0.000 description 5
- 229940052760 dopamine agonists Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000009871 nonspecific binding Effects 0.000 description 5
- 229940005483 opioid analgesics Drugs 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YXFVVABEGXRONW-UHFFFAOYSA-N CC1=CC=CC=C1 Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- QWLMBPWNPGUBMQ-UHFFFAOYSA-N COCCOC1=CC=C(N2CCN(C)CC2)C=C1 Chemical compound COCCOC1=CC=C(N2CCN(C)CC2)C=C1 QWLMBPWNPGUBMQ-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 208000001431 Psychomotor Agitation Diseases 0.000 description 4
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960003284 iron Drugs 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 3
- DKGBYVNZYFLWPK-UHFFFAOYSA-N CC(C)(C)C.CC(C)(C)C#N.CC(C)(C)O.CN(C)C.[H]C(C)(C)C Chemical compound CC(C)(C)C.CC(C)(C)C#N.CC(C)(C)O.CN(C)C.[H]C(C)(C)C DKGBYVNZYFLWPK-UHFFFAOYSA-N 0.000 description 3
- BTQZKHUEUDPRST-UHFFFAOYSA-N CC1=CC(F)=CC=C1 Chemical compound CC1=CC(F)=CC=C1 BTQZKHUEUDPRST-UHFFFAOYSA-N 0.000 description 3
- CATAGJZATFZGMJ-UHFFFAOYSA-N CC1=CN=C(N2CCN(C)CC2)C=C1 Chemical compound CC1=CN=C(N2CCN(C)CC2)C=C1 CATAGJZATFZGMJ-UHFFFAOYSA-N 0.000 description 3
- PYEHNKXDXBNHQQ-UHFFFAOYSA-N CN1C(=O)NC2=C1C=CC=C2 Chemical compound CN1C(=O)NC2=C1C=CC=C2 PYEHNKXDXBNHQQ-UHFFFAOYSA-N 0.000 description 3
- WQDDXVGJRSTLED-UHFFFAOYSA-N CN1CCN(C2=CC=CC=C2)CC1 Chemical compound CN1CCN(C2=CC=CC=C2)CC1 WQDDXVGJRSTLED-UHFFFAOYSA-N 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000282676 Sapajus apella Species 0.000 description 3
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 3
- NNPPMTNAJDCUHE-UHFFFAOYSA-N [H]C(C)(C)C Chemical compound [H]C(C)(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 229960003089 pramipexole Drugs 0.000 description 3
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 description 2
- FFBDFADSZUINTG-LEZITTIZSA-N 8-cyclopentyl-1,3-bis(1,3-ditritiopropyl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C([3H])CC[3H])C(=O)N(C([3H])CC[3H])C=2N=C1C1CCCC1 FFBDFADSZUINTG-LEZITTIZSA-N 0.000 description 2
- 102000009346 Adenosine receptors Human genes 0.000 description 2
- 108050000203 Adenosine receptors Proteins 0.000 description 2
- FCTDONYXEVQRPC-UHFFFAOYSA-N C.C.CC(C)C.CN(C)C Chemical compound C.C.CC(C)C.CN(C)C FCTDONYXEVQRPC-UHFFFAOYSA-N 0.000 description 2
- NIBCHLGCVVSHOD-UHFFFAOYSA-N C=C(C)C.COCC1(C)OCCO1 Chemical compound C=C(C)C.COCC1(C)OCCO1 NIBCHLGCVVSHOD-UHFFFAOYSA-N 0.000 description 2
- ORSLWWZNGBJVIW-UHFFFAOYSA-N CC(C)N(C)CCN1CCN(C2=CC=C(F)C=C2F)CC1 Chemical compound CC(C)N(C)CCN1CCN(C2=CC=C(F)C=C2F)CC1 ORSLWWZNGBJVIW-UHFFFAOYSA-N 0.000 description 2
- 125000006519 CCH3 Chemical group 0.000 description 2
- HJKYBFCODNYSHS-UHFFFAOYSA-N CCN(C)CCN1CCN(C2=CC=C(F)C=C2F)CC1 Chemical compound CCN(C)CCN1CCN(C2=CC=C(F)C=C2F)CC1 HJKYBFCODNYSHS-UHFFFAOYSA-N 0.000 description 2
- FRKDKQXJOOSEHE-UHFFFAOYSA-N CN1CCN(C2=C(F)C=C(F)C=C2F)CC1 Chemical compound CN1CCN(C2=C(F)C=C(F)C=C2F)CC1 FRKDKQXJOOSEHE-UHFFFAOYSA-N 0.000 description 2
- OUDJYEDSHVUQCS-UHFFFAOYSA-N CN1CCN(C2=CC=C(Cl)C=C2F)CC1 Chemical compound CN1CCN(C2=CC=C(Cl)C=C2F)CC1 OUDJYEDSHVUQCS-UHFFFAOYSA-N 0.000 description 2
- YODLIZLCKLQILI-UHFFFAOYSA-N CN1CCN(C2=NC=C(F)C=N2)CC1 Chemical compound CN1CCN(C2=NC=C(F)C=N2)CC1 YODLIZLCKLQILI-UHFFFAOYSA-N 0.000 description 2
- KOBDKUVEIRTGAJ-UHFFFAOYSA-N COC(=O)N1CCCC1C Chemical compound COC(=O)N1CCCC1C KOBDKUVEIRTGAJ-UHFFFAOYSA-N 0.000 description 2
- ZOXQLBQHWUVIIA-UHFFFAOYSA-N COC1=C(OC)C=C(N2CCN(C)CC2)C(F)=C1 Chemical compound COC1=C(OC)C=C(N2CCN(C)CC2)C(F)=C1 ZOXQLBQHWUVIIA-UHFFFAOYSA-N 0.000 description 2
- JUQQCVRAZHUCLU-UHFFFAOYSA-N COCCOC1=CC(F)=C(N2CCN(C)CC2)C(F)=C1 Chemical compound COCCOC1=CC(F)=C(N2CCN(C)CC2)C(F)=C1 JUQQCVRAZHUCLU-UHFFFAOYSA-N 0.000 description 2
- 208000009132 Catalepsy Diseases 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- UTLPKQYUXOEJIL-UHFFFAOYSA-N LSM-3822 Chemical compound N1=CC=2C3=NC(C=4OC=CC=4)=NN3C(N)=NC=2N1CCC1=CC=CC=C1 UTLPKQYUXOEJIL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JADDQZYHOWSFJD-FLNNQWSLSA-N N-ethyl-5'-carboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 JADDQZYHOWSFJD-FLNNQWSLSA-N 0.000 description 2
- JZAMQDDHRXHDFR-UHFFFAOYSA-N NC1=NC2=C(C=NN2CCN2CCN(C3=C(F)C=C(F)C=C3)CC2)C2=NC(C3=CC=CO3)=NN12 Chemical compound NC1=NC2=C(C=NN2CCN2CCN(C3=C(F)C=C(F)C=C3)CC2)C2=NC(C3=CC=CO3)=NN12 JZAMQDDHRXHDFR-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- 206010047853 Waxy flexibility Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229940127236 atypical antipsychotics Drugs 0.000 description 2
- 125000003725 azepanyl group Chemical group 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 2
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- OKJAHFUTJQJIPM-UHFFFAOYSA-N C.C.C.C.C.C.C.CC(C)(C)OC(=O)N1CCN(C2=C(CNC3=CC4=NC(C5=CC=CO5)=NN4C(N)=N3)C=CC=C2)CC1.CCOC(=O)N(CC)C1CCN(C2=CC=CC(C3=CC4=NC(C5=CC=CO5)=NN4C(N)=N3)=C2)CC1.CCOC(=O)N1CCN(C2=CC=CC(C3=CC4=NC(C5=CC=CO5)=NN4C(N)=N3)=C2)CC1.COCCN(CC1=C(OC)C=CC=C1OC)C1=CC2=NC(C3=CC=CO3)=NN2C(N)=N1.NC1=NC(C2=CC(N3CCN(C(=O)CN4CCOCC4)CC3)=CC=C2)=CC2=NC(C3=CC=CO3)=NN12.NC1=NC(C2=CC(N3CCN(CCN4CCOCC4)CC3)=CC=C2)=CC2=NC(C3=CC=CO3)=NN12.NC1=NC(C2=CC=NC=C2)=CC2=NC(C3=CC=CO3)=NN12 Chemical compound C.C.C.C.C.C.C.CC(C)(C)OC(=O)N1CCN(C2=C(CNC3=CC4=NC(C5=CC=CO5)=NN4C(N)=N3)C=CC=C2)CC1.CCOC(=O)N(CC)C1CCN(C2=CC=CC(C3=CC4=NC(C5=CC=CO5)=NN4C(N)=N3)=C2)CC1.CCOC(=O)N1CCN(C2=CC=CC(C3=CC4=NC(C5=CC=CO5)=NN4C(N)=N3)=C2)CC1.COCCN(CC1=C(OC)C=CC=C1OC)C1=CC2=NC(C3=CC=CO3)=NN2C(N)=N1.NC1=NC(C2=CC(N3CCN(C(=O)CN4CCOCC4)CC3)=CC=C2)=CC2=NC(C3=CC=CO3)=NN12.NC1=NC(C2=CC(N3CCN(CCN4CCOCC4)CC3)=CC=C2)=CC2=NC(C3=CC=CO3)=NN12.NC1=NC(C2=CC=NC=C2)=CC2=NC(C3=CC=CO3)=NN12 OKJAHFUTJQJIPM-UHFFFAOYSA-N 0.000 description 1
- YGKZRVJRECRHDD-UHFFFAOYSA-N C.C.C.C.C.C.CC(C)S(=O)(=O)N1CCN(C2=CC=CC(C3=CC4=NC(C5=CC=CO5)=NN4C(N)=N3)=C2)CC1.CCN(C(=O)C(C)C)C1CCN(C2=CC=CC(C3=CC4=NC(C5=CC=CO5)=NN4C(N)=N3)=C2)CC1.COCCOC1=CC=C(N2CCN(C3=CC=CC(C4=CC5=NC(C6=CC=CO6)=NN5C(N)=N4)=C3)CC2)C=C1.COCCOC1=CC=C(N2CCN(CC3=CC=CC(C4=CC5=NC(C6=CC=CO6)=NN5C(N)=N4)=C3)CC2)C=C1.NC1=NC(C2=CC(N3CCC(N4CCOCC4)CC3)=CC=C2)=CC2=NC(C3=CC=CO3)=NN12.NC1=NC(C2=CC(N3CCN(CC4=CC=CC=C4)CC3)=CC=C2)=CC2=NC(C3=CC=CO3)=NN12 Chemical compound C.C.C.C.C.C.CC(C)S(=O)(=O)N1CCN(C2=CC=CC(C3=CC4=NC(C5=CC=CO5)=NN4C(N)=N3)=C2)CC1.CCN(C(=O)C(C)C)C1CCN(C2=CC=CC(C3=CC4=NC(C5=CC=CO5)=NN4C(N)=N3)=C2)CC1.COCCOC1=CC=C(N2CCN(C3=CC=CC(C4=CC5=NC(C6=CC=CO6)=NN5C(N)=N4)=C3)CC2)C=C1.COCCOC1=CC=C(N2CCN(CC3=CC=CC(C4=CC5=NC(C6=CC=CO6)=NN5C(N)=N4)=C3)CC2)C=C1.NC1=NC(C2=CC(N3CCC(N4CCOCC4)CC3)=CC=C2)=CC2=NC(C3=CC=CO3)=NN12.NC1=NC(C2=CC(N3CCN(CC4=CC=CC=C4)CC3)=CC=C2)=CC2=NC(C3=CC=CO3)=NN12 YGKZRVJRECRHDD-UHFFFAOYSA-N 0.000 description 1
- KDIXWUBJWXOATH-UHFFFAOYSA-N C.C.C.C.CC(=O)C(C)(C)C.CC(C)(C)C#N.CC(C)(C)O.CC(C)C.CN(C)C Chemical compound C.C.C.C.CC(=O)C(C)(C)C.CC(C)(C)C#N.CC(C)(C)O.CC(C)C.CN(C)C KDIXWUBJWXOATH-UHFFFAOYSA-N 0.000 description 1
- BKOVLGUONDUQPW-UHFFFAOYSA-N C.C.C.C.CC1=CC(C)=CC(C2=CC3=NC(C4=CC=CO4)=NN3C(N)=N2)=C1.COCCOC1=CC(F)=C(N2CCN(CC3=CC=CC(C4=CC5=NC(C6=CC=CO6)=NN5C(N)=N4)=C3)CC2)C=C1.NC1=NC(C2=CC(CO)=CC=C2)=CC2=NC(C3=CC=CO3)=NN12 Chemical compound C.C.C.C.CC1=CC(C)=CC(C2=CC3=NC(C4=CC=CO4)=NN3C(N)=N2)=C1.COCCOC1=CC(F)=C(N2CCN(CC3=CC=CC(C4=CC5=NC(C6=CC=CO6)=NN5C(N)=N4)=C3)CC2)C=C1.NC1=NC(C2=CC(CO)=CC=C2)=CC2=NC(C3=CC=CO3)=NN12 BKOVLGUONDUQPW-UHFFFAOYSA-N 0.000 description 1
- OZAQDMWMJHKDQH-UHFFFAOYSA-N C.C.C1=COCC1.C1CCOC1.CC(C)C.CC(C)C Chemical compound C.C.C1=COCC1.C1CCOC1.CC(C)C.CC(C)C OZAQDMWMJHKDQH-UHFFFAOYSA-N 0.000 description 1
- WJAGNCOGHZFRPJ-UHFFFAOYSA-N C.C.C=C(C)C(C)C.CC(C)C(=O)OCC1=CC=CC=C1.CC(C)OCC1(C)OCCO1 Chemical compound C.C.C=C(C)C(C)C.CC(C)C(=O)OCC1=CC=CC=C1.CC(C)OCC1(C)OCCO1 WJAGNCOGHZFRPJ-UHFFFAOYSA-N 0.000 description 1
- PNFZWFBYWNZYSG-UHFFFAOYSA-N C.C=C(C)C.COCC1(C)OCCO1 Chemical compound C.C=C(C)C.COCC1(C)OCCO1 PNFZWFBYWNZYSG-UHFFFAOYSA-N 0.000 description 1
- ZLQCQRJHAVDVBV-UHFFFAOYSA-N C.CC(C)C Chemical compound C.CC(C)C ZLQCQRJHAVDVBV-UHFFFAOYSA-N 0.000 description 1
- AZVZLCWLZHUUIZ-UHFFFAOYSA-N C.CC(C)C.COCC1(C)OCCO1 Chemical compound C.CC(C)C.COCC1(C)OCCO1 AZVZLCWLZHUUIZ-UHFFFAOYSA-N 0.000 description 1
- KHRIPQMMFOGLOF-UHFFFAOYSA-N C.CN(C)C Chemical compound C.CN(C)C KHRIPQMMFOGLOF-UHFFFAOYSA-N 0.000 description 1
- RWXYYIZMIFAUKR-UHFFFAOYSA-N C.COC(=O)N1CCCC1C Chemical compound C.COC(=O)N1CCCC1C RWXYYIZMIFAUKR-UHFFFAOYSA-N 0.000 description 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
- HHXAQFKCNXFZTK-UHFFFAOYSA-N C1=C2CCCCC2=CC1.C1=CC=C2CCCCC2=C1.C1CCC2=C(C1)CCC2 Chemical compound C1=C2CCCCC2=CC1.C1=CC=C2CCCCC2=C1.C1CCC2=C(C1)CCC2 HHXAQFKCNXFZTK-UHFFFAOYSA-N 0.000 description 1
- FANWFQBOTIRDAB-UHFFFAOYSA-N C1=COCC1.C1CCOC1.CC(C)(C)C.CC(C)C Chemical compound C1=COCC1.C1CCOC1.CC(C)(C)C.CC(C)C FANWFQBOTIRDAB-UHFFFAOYSA-N 0.000 description 1
- QMEKHVBDVPQBTN-UHFFFAOYSA-N C=CCN(C)CCN1CCN(C2=CC=C(OCCOC)C=C2)CC1 Chemical compound C=CCN(C)CCN1CCN(C2=CC=C(OCCOC)C=C2)CC1 QMEKHVBDVPQBTN-UHFFFAOYSA-N 0.000 description 1
- YPWKAZSHYHFTIW-UHFFFAOYSA-N CC(=O)N1CCCC1C Chemical compound CC(=O)N1CCCC1C YPWKAZSHYHFTIW-UHFFFAOYSA-N 0.000 description 1
- GXQFUMWJAPMOIO-UHFFFAOYSA-N CC(=O)N1CCCC1C(C)C Chemical compound CC(=O)N1CCCC1C(C)C GXQFUMWJAPMOIO-UHFFFAOYSA-N 0.000 description 1
- DPWOOYNZTLMISP-UHFFFAOYSA-N CC(C)C(C#N)(C(C)C)C(C)C.CC(C)C(C)(C(C)C)C(C)C.CC(C)C(O)(C(C)C)C(C)C.CC(C)N(C(C)C)C(C)C.[H]C(C(C)C)(C(C)C)C(C)C Chemical compound CC(C)C(C#N)(C(C)C)C(C)C.CC(C)C(C)(C(C)C)C(C)C.CC(C)C(O)(C(C)C)C(C)C.CC(C)N(C(C)C)C(C)C.[H]C(C(C)C)(C(C)C)C(C)C DPWOOYNZTLMISP-UHFFFAOYSA-N 0.000 description 1
- YVYHOOYMDHZALB-UHFFFAOYSA-N CC(C)C(C(C)C)C(C)C Chemical compound CC(C)C(C(C)C)C(C)C YVYHOOYMDHZALB-UHFFFAOYSA-N 0.000 description 1
- KALNRVPTCYZOAY-UHFFFAOYSA-N CC(C)C.CN(C)C Chemical compound CC(C)C.CN(C)C KALNRVPTCYZOAY-UHFFFAOYSA-N 0.000 description 1
- PHNGKBZPSNEOMR-UHFFFAOYSA-N CC(C)OCC1(C)OCCO1 Chemical compound CC(C)OCC1(C)OCCO1 PHNGKBZPSNEOMR-UHFFFAOYSA-N 0.000 description 1
- WOEAYEKRTHZLKF-UHFFFAOYSA-N CC1=CC=C2CCN(CCN3N=CC4=C3N=C(N)N3N=C(C5=CC=CO5)N=C43)CCC2=C1.CC1=CN=C2CCN(CCN3/N=C\C4=C3N=C(N)N3N=C(C5=CC=CO5)N=C43)CC2=C1.COC1=CC2=C(C=C1C)CC(C)N(CCN1N=CC3=C1N=C(N)N1N=C(C4=CC=CO4)N=C31)C2.COC1=CC2=C(C=C1OC)C(CC1=CC=CC=C1)N(CCN1N=CC3=C1N=C(N)N1N=C(C4=CC=CO4)N=C31)CC2.COCCOC1=CC=C2CCN(CCN3N=CC4=C3N=C(N)N3N=C(C5=CC=CO5)N=C43)CCC2=C1.NC1=NC2=C(C=NN2CCN2CCC3=CC=CC=C3CC2)C2=NC(C3=CC=CO3)=NN12 Chemical compound CC1=CC=C2CCN(CCN3N=CC4=C3N=C(N)N3N=C(C5=CC=CO5)N=C43)CCC2=C1.CC1=CN=C2CCN(CCN3/N=C\C4=C3N=C(N)N3N=C(C5=CC=CO5)N=C43)CC2=C1.COC1=CC2=C(C=C1C)CC(C)N(CCN1N=CC3=C1N=C(N)N1N=C(C4=CC=CO4)N=C31)C2.COC1=CC2=C(C=C1OC)C(CC1=CC=CC=C1)N(CCN1N=CC3=C1N=C(N)N1N=C(C4=CC=CO4)N=C31)CC2.COCCOC1=CC=C2CCN(CCN3N=CC4=C3N=C(N)N3N=C(C5=CC=CO5)N=C43)CCC2=C1.NC1=NC2=C(C=NN2CCN2CCC3=CC=CC=C3CC2)C2=NC(C3=CC=CO3)=NN12 WOEAYEKRTHZLKF-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N CC1=CC=CC=C1C Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- DVFVNJHIVAPTMS-UHFFFAOYSA-N CC1=CC=CC=C1C(F)(F)F Chemical compound CC1=CC=CC=C1C(F)(F)F DVFVNJHIVAPTMS-UHFFFAOYSA-N 0.000 description 1
- MMZYCBHLNZVROM-UHFFFAOYSA-N CC1=CC=CC=C1F Chemical compound CC1=CC=CC=C1F MMZYCBHLNZVROM-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N CC1=CC=CC=N1 Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- HKUVCJBKEOIQFL-UHFFFAOYSA-N CC1=CN=C(N2CCN(C)CC2)N=C1 Chemical compound CC1=CN=C(N2CCN(C)CC2)N=C1 HKUVCJBKEOIQFL-UHFFFAOYSA-N 0.000 description 1
- MFNSMYPVPWCVBP-UHFFFAOYSA-N CCCN(C)CCN1CCN(C2=CC=C(OCCOC)C=C2)CC1 Chemical compound CCCN(C)CCN1CCN(C2=CC=C(OCCOC)C=C2)CC1 MFNSMYPVPWCVBP-UHFFFAOYSA-N 0.000 description 1
- YAAUMFLIYYFQJU-UHFFFAOYSA-N CN(C)CCN1CCN(C2=CC=C(F)C=C2F)CC1 Chemical compound CN(C)CCN1CCN(C2=CC=C(F)C=C2F)CC1 YAAUMFLIYYFQJU-UHFFFAOYSA-N 0.000 description 1
- OTQZOTVGHWDHKR-UHFFFAOYSA-N CN(CCN1CCN(C2=CC=C(F)C=C2F)CC1)CC1CC1 Chemical compound CN(CCN1CCN(C2=CC=C(F)C=C2F)CC1)CC1CC1 OTQZOTVGHWDHKR-UHFFFAOYSA-N 0.000 description 1
- LFLGMXNQCKJNDQ-UHFFFAOYSA-N CN1CCC2=C(C1)[W]=[V][U]=N2 Chemical compound CN1CCC2=C(C1)[W]=[V][U]=N2 LFLGMXNQCKJNDQ-UHFFFAOYSA-N 0.000 description 1
- BGVQAXHXGFPYTQ-UHFFFAOYSA-N CN1CCN(C2=CC=CC(Cl)=C2)CC1 Chemical compound CN1CCN(C2=CC=CC(Cl)=C2)CC1 BGVQAXHXGFPYTQ-UHFFFAOYSA-N 0.000 description 1
- OSPDKPFPBGJRTD-UHFFFAOYSA-N CN1CCN(C2=NC=CS2)CC1 Chemical compound CN1CCN(C2=NC=CS2)CC1 OSPDKPFPBGJRTD-UHFFFAOYSA-N 0.000 description 1
- XFPREISSKGHAIT-UHFFFAOYSA-N COCCN(C)CCN1CCN(C2=CC=C(F)C=C2F)CC1 Chemical compound COCCN(C)CCN1CCN(C2=CC=C(F)C=C2F)CC1 XFPREISSKGHAIT-UHFFFAOYSA-N 0.000 description 1
- RIMFQBHIYKXSJN-UHFFFAOYSA-N COCCOC1=CC=C(N2CCN(CCN(C)C)CC2)C(F)=C1 Chemical compound COCCOC1=CC=C(N2CCN(CCN(C)C)CC2)C(F)=C1 RIMFQBHIYKXSJN-UHFFFAOYSA-N 0.000 description 1
- ZYKDCTRKFBNPIV-UHFFFAOYSA-N COCCOC1=CC=C(N2CCN(CCN(C)C3CC3)CC2)C=C1 Chemical compound COCCOC1=CC=C(N2CCN(CCN(C)C3CC3)CC2)C=C1 ZYKDCTRKFBNPIV-UHFFFAOYSA-N 0.000 description 1
- PRWDGNFVLLKWSS-UHFFFAOYSA-N COCCOC1=CC=C(N2CCN(CCN(C)CC(F)(F)F)CC2)C=C1 Chemical compound COCCOC1=CC=C(N2CCN(CCN(C)CC(F)(F)F)CC2)C=C1 PRWDGNFVLLKWSS-UHFFFAOYSA-N 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 206010008752 Choreiform movements Diseases 0.000 description 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 229910020008 S(O) Inorganic materials 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 230000003270 anti-cataleptic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940124604 anti-psychotic medication Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000002903 catalepsic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000000442 dopamine 2 receptor blocking agent Substances 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960002724 fenoldopam Drugs 0.000 description 1
- TVURRHSHRRELCG-UHFFFAOYSA-N fenoldopam Chemical compound C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 TVURRHSHRRELCG-UHFFFAOYSA-N 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 125000000879 imine group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 208000023515 periodic limb movement disease Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003188 temazepam Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the use of adenosine A 2a receptor antagonists for the treatment of a variety of neurological syndromes involving the extra-pyramidal motor system (i.e. Extra-Pyramidal Syndrome) that occur following the acute and chronic use of almost all antipsychotic drugs.
- the invention also relates to the use of adenosine A 2a receptor antagonists for the treatment of other abnormal movement disorders such as restless leg syndrome (RLS) and periodic limb movement in sleep (PLMS).
- RLS restless leg syndrome
- PLMS periodic limb movement in sleep
- Extra-Pyramidal Syndrome is a collective term for a series of adverse neurological reactions associated with the use of antipsychotic drugs.
- EPS-related neurological syndromes There are six different categories of EPS-related neurological syndromes of which four, dystonia, akathisia, pseudoparkinsonism (parkinsonian syndrome), and tardive dyskinesia, are particularly prevalent in patients taking antipsychotic medication.
- Dystonia is a painful spasm of the muscle groups of, in particular, the neck, jaw, back, pharynx, and larynx. It is most common in young males being treated with antipsychotic drugs, but can also be associated with the use of cocaine, tricyclic antidepressants, lithium and anticonvulsants such as phenyloin and carbamazepine.
- Pseudoparkinsonism manifests itself as akinesia (rigidity, stiffness and slow voluntary motion, stooped, shuffling walk) and tremor and these symptoms develop within weeks or months after initiation of therapy.
- Akathisia manifests itself as strong, subjective inner feelings of distress or discomfort characterized by motor restlessness. Often mistaken for agitation or anxiety, this common syndrome is frequently under-diagnosed and is the least responsive to treatment.
- Tardive dyskinesia is a late-appearing syndrome associated with chronic use of neuroleptic drugs. It occurs more frequently in older patients and is characterized by stereotypical, repetitive, involuntary, quick choreiform movements of the face, eyelids, mouth, tongue, extremities and trunk.
- EPS is more prevalent with the use of typical antipsychotic agents but has also been reported with the use of atypical agents.
- Typical antipsychotics include loxapine, haloperidol, chlorpromazine, prochlorperazine and thiothixene.
- Atypical antipsychotics include clozapine, olanzapine, loxapine, quetiapine, ziprasidone and risperidone.
- RLS is a common disorder that causes patients to have an irresistible and unpleasant desire to move their legs; it usually manifests during periods of inactivity and/or at night, and can disturb sleep. Patients who do not have the typical RLS symptoms, but who do exhibit periodic leg movements that adversely impact sleep, are diagnosed with PLMS.
- RLS and PLMS Treatments for RLS and PLMS have included levodopa/carbidopa, levodopa/benserazide, dopamine agonists such as pramipexole and ropinerole, benzodiazepines, opioids, anticonvulsants and iron (ferrous sulfate).
- RLS and PLMS have been extensively described in the literature, for example by Saletu et al, Neuropsvchobiology, 41, 4 (2000), p. 190-9.
- the purine nucleotide, adenosine is known to be an endogenous modulator of a number of physiological functions in the central (CNS) and peripheral nervous systems.
- Adenosine exerts its biological actions through a class of membrane specific receptors which belong to the super family of receptors coupled with G proteins. Biochemical and pharmacological studies, together with advances in molecular biology, have allowed the identification of at least four subtypes of adenosine receptors: A 1 , A 2a , A 2b and A 3 . Analogs of adenosine able to interact as antagonists with the A 1 , A 2a , A 2b and A 3 receptors have also been identified.
- a 2a receptors are present in high density in the basal ganglia, known to be important in the control of fine motor movement.
- selective antagonists for the A 2a receptor are of pharmacological interest because of their demonstrated efficacy in reducing motor impairment thereby improving function in neurodegenerative diseases such as Parkinson's disease and related movement disorders (e.g. Huntington's Disease).
- a 2a antagonists appear to demonstrate a reduced side-effect liability (e.g. no dyskinesia) compared to current dopaminergic therapies resulting in an improved therapeutic index.
- a 2a antagonists may also have antidepressant properties and stimulate cognitive functions.
- xanthine-related compounds have been found to be A 1 receptor selective antagonists, and xanthine and non-xanthine compounds have been found to have high A 2a affinity with varying decrees of A 2a vs. A 1 selectivity.
- Adenosine A 2a receptor antagonists have been disclosed previously, for example in WO 95/01356 and U.S. Pat. No. 6,630,475.
- This invention relates to a method for the treatment or prevention of Extra-Pyramidal Syndrome (e.g., dystonia, akathisia, pseudoparkinsonism and tardive dyskinesia) comprising administering a therapeutically effective amount of an adenosine A 2a receptor antagonist to a patient in need thereof.
- this method is for the treatment or prevention of EPS in patients treated with an antipsychotic agent that has the side effect of inducing EPS.
- the adenosine A 2a receptor antagonist can be administered after the symptoms of EPS have manifested, or an adenosine A 2a receptor antagonist can be administered at the onset of administering an antipsychotic agent in order to prevent EPS from occurring.
- the invention also includes a method of treating or preventing EPS induced by an antipsychotic agent comprising administering a combination of an antipsychotic agent and an adenosine A 2a antagonist to a patient in need thereof. More particularly, the invention relates to the method of using of certain adenosine A 2a antagonists for the monotherapy or the combined therapy.
- the invention also relates to the treatment of primary (idiopathic) dystonia, and to the treatment or prevention of dystonia in patients who exhibit dystonia as a result of treatment with a tricyclic antidepressant, lithium or an anticonvulsant, or who have used cocaine, comprising administering a therapeutically effective amount of an adenosine A 2a receptor antagonist to a patient in need thereof.
- the adenosine A 2a receptor antagonist When dystonia is caused by treatment with a tricyclic antidepressant, lithium or an anticonvulsant, the adenosine A 2a receptor antagonist can be administered after the symptoms of dystonia have manifested, or an adenosine A 2a receptor antagonist can be administered at the onset of administering a tricyclic antidepressant, lithium or an anticonvulsant in order to prevent dystonia from occurring.
- the invention therefore, also includes a method of treating or preventing dystonia induced by a tricyclic antidepressant, lithium or an anticonvulsant comprising administering a combination of an adenosine A 2a antagonist and a tricyclic antidepressant, lithium or an anticonvulsant to a patient in need thereof.
- the invention also relates to the treatment of RLS or PLMS, comprising administering to a patient in need thereof a therapeutically effective amount of an adenosine A 2a receptor antagonist.
- the invention also comprises a method of treating RLS or PLMS comprising administering a combination of an adenosine A 2a antagonist with another agent useful in treating RLS or PLMS, such as levodopa/carbidopa, levodopa/benserazide, a dopamine agonist, a benzodiazepine, an opioid, an anticonvulsant or iron, to a patient in need thereof.
- this invention relates to a kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat or prevent EPS caused by treatment with antipsychotic agent, wherein one container comprises a pharmaceutical composition comprising an effective amount of an adenosine A 2a receptor antagonist in a pharmaceutically acceptable carrier, and wherein a separate container comprises a pharmaceutical composition comprising an effective amount of an antipsychotic agent.
- this invention relates to a kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat or prevent dystonia caused by treatment with a tricyclic antidepressant, lithium or an anticonvulsant, wherein one container comprises a pharmaceutical composition comprising an effective amount of an adenosine A 2a receptor antagonist in a pharmaceutically acceptable carrier, and wherein a separate container comprises a pharmaceutical composition comprising an effective amount of a tricyclic antidepressant, lithium or an anticonvulsant.
- this invention relates to a kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat RLS or PLMS, wherein one container comprises a pharmaceutical composition comprising an effective amount of an adenosine A 2a receptor antagonist in a pharmaceutically acceptable carrier, and wherein a separate container comprises a pharmaceutical composition comprising an effective amount of levodopa/carbidopa, levodopa/benserazide, a dopamine agonist, a benzodiazepine, an opioid, an anticonvulsant or iron.
- the invention also relates to the use of an adenosine A 2a receptor antagonist for the preparation of a medicament for treating or preventing EPS, dystonia, RLS or PLMS, alone or in combination with the other agents discussed above.
- FIG. 1A illustrates the effect of Compound A (1-30 mg/kg, p.o.) on maximum EPS score.
- FIG. 1B represents the mean delay in onset of EPS for each treatment group compared to a vehicle control group.
- Any adenosine A 2a receptor antagonist is contemplated for use in the method of this invention.
- Suitable adenosine A 2a receptor antagonists useful in the method of the invention can be identified by the binding assay described below.
- Specific examples of suitable adenosine A 2a antagonists include the compounds disclosed in several patents and patent applications, e.g. WO 95/01356; U.S. Pat. No. 5,565,460; U.S. Pat. No. 6,630,475 B2; U.S. Pat. No. 5,935,964; WO 03/032996; WO 03/048165; WO 03/048164; WO 03/048163; and WO 01/02409. Specifically, these patents and applications disclose the following compounds.
- R is R 1 -furanyl, R 1 -thienyl, R 1 -pyridyl, R 1 -pyridyl N-oxide, R 1 -oxazolyl, R 10 -phenyl, R 1 -pyrrolyl or C 4 -C 6 cycloalkenyl;
- X is C 2 -C 6 alkylene or —C(O)CH 2 —;
- Y is —N(R 2 )CH 2 CH 2 N(R 3 )—, —OCH 2 CH 2 N(R 2 )—, —O—, —S—, —CH 2 S—, —(CH 2 ) 2 —NH—, or
- Z is R 5 -phenyl, R 5 -phenyl(C 1 -C 6 )alkyl, R 5 -heteroaryl, diphenylmethyl, R 6 —C(O)—,
- R 6 SO, R 6 —OC(O)—, R 7 —N(R 8 )—C(O)—, R 7 —N(R 8 )—C(S)—,
- Z is also phenylamino or pyridylamino
- R 1 is 1 to 3 substituents independently selected from hydrogen, C 1 -C 6 -alkyl, —CF 3 , halogen, —NO 2 , —NR 12 R 13 , C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, —C 6 alkylsulfinyl, and C 1 -C 6 alkylsulfonyl;
- R 2 and R 3 are independently selected from the group consisting of hydrogen and C 1 -C 6 alkyl
- R 4 is 1-2 substituents independently selected from the group consisting of hydrogen and C 1 -C 6 alkyl, or two R 4 substituents on the same carbon can form ⁇ O;
- R 5 is 1 to 5 substituents independently selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, —CN, di-((C 1 -C 6 )alkyl)amino, —CF 3 , —OCF 3 , acetyl, —NO 2 , hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )-alkoxy(C 1 -C 6 )alkoxy, di-((C 1 -C 6 )-alkoxy)(C 1 -C 6 )alkoxy, (C 1 -C 6 )-alkoxy(C 1 -C 6 )alkoxy-(C 1 -C 6 )-alkoxy, carboxy(C 1 -C 6 )-alkoxy, (C 1 -C 6 )-alkoxycarbonyl(C 1 -C 6 )alkoxy, (C 3
- R 5 substituents together are —O—CH 2 —O—, —O—CH 2 CH 2 —O—, —O—CF 2 —O— or —O—CF 2 CF 2 —O— and form a ring with the carbon atoms to which they are attached;
- R 6 is (C 1 -C 6 )alkyl, R 5 -phenyl, R 5 -phenyl(C 1 -C 6 )alkyl, thienyl, pyridyl, (C 3 -C 6 )-cycloalkyl, (C 1 -C 6 )alkyl-OC(O)NH—(C 1 -C 6 )alkyl-, di-((C 1 -C 6 )alkyl)aminomethyl, or
- R 7 is (C 1 -C 6 )alkyl, R 5 -phenyl or R 5 -phenyl(C 1 -C 6 )alkyl;
- R 8 is hydrogen or C 1 -C 6 alkyl; or R 7 and R 8 together are —(CH 2 ) p -A-(CH 2 ) q , wherein p and q are independently 2 or 3 and A is a bond, —CH 2 —, —S— or —O—, and form a ring with the nitrogen to which they are attached;
- R 9 is 1-2 groups independently selected from hydrogen, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, halogen, —CF 3 and (C 1 -C 6 )alkoxy(C 1 -C 6 )alkoxy;
- R 10 is 1 to 5 substituents independently selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, —CN, —NH 2 , C 1 -C 6 alkylamino, di-((C 1 -C 6 )alkyl)amino, —CF 3 , —OCF 3 and —S(O) 0-2 (C 1 -C 6 )alkyl;
- R 11 is H, C 1 -C 6 alkyl, phenyl, benzyl, C 2 -C 6 alkenyl, C 1 -C 6 alkoxy(C 1 -C 6 )alkyl, di-((C 1 -C 6 )alkyl)amino(C 1 -C 6 )alkyl, pyrrolidinyl(C 1 -C 6 )alkyl or piperidino(C 1 -C 6 )alkyl;
- R 12 is H or C 1 -C 6 alkyl
- R 13 is (C 1 -C 6 )alkyl-C(O)— or (C 1 -C 6 )alkyl-SO 2 —.
- Preferred compounds of formula I are those wherein R is R 1 -furanyl, R 1 -thienyl, R 1 -pyrrolyl or R 10 -phenyl, more preferably R 1 -furanyl.
- R 1 is preferably hydrogen or halogen.
- Another group of preferred compounds is that wherein X is alkylene, preferably ethylene.
- Y is preferably
- R 4 is H.
- a preferred definition for Z is R 5 -phenyl, R 5 -heteroaryl, R 6 —C(O)— or R 6 —SO 2 —.
- R 5 is preferably H, halogen, alkyl, alkoxy, hydroxyalkoxy or alkoxyalkoxy.
- R 6 is preferably R 5 -phenyl.
- Preferred specific compounds of formula I are those of the formula IA
- R and Z-Y are as defined in the following table:
- adenosine A 2a receptor antagonists include those disclosed in WO 95/01356 as compounds having the structural formula II
- A is pyrazole, imidazole or a triazole ring
- R is hydrogen; C 1 -C 8 alkyl; C 3 -C 7 alkenyl; C 3 -C 7 alkynyl; C 3 -C 7 cycloalkyl; C 1 -C 5 alkyl substituted with one or more halogen atoms, hydroxy groups, C 1 -C 4 alkoxy, C 3 -C 7 cycloalkyl, groups of formula —NR 1 R 2 , —CONR 1 R 2 ; aryl optionally substituted with halogen atoms, C 1 -C 4 alkoxy groups, C 1 -C 4 alkyl, nitro, amino, cyano, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, carboxy, carboxyamido; C 7 -C 10 aralkyl in which the aryl moiety can be substituted with one or more of the substituents indicated above for the aryl group; a group of formula —(CH 2 ) m
- R 1 , R 2 which are the same or different, are hydrogen, C 1 -C 5 alkyl, C 7 -C 10 aralkyl, phenyl, or taken together with the nitrogen they are linked to, form an azetidine ring or a 5-6 membered heterocyclic ring containing one or more heteroatoms such as N, O, S and n is an integer from 2 to 5.
- compounds of formula II are those wherein R is hydrogen, C 1 -C 8 alkyl, aryl or C 7 -C 10 aralkyl optionally substituted, preferably with halogen atoms.
- A is pyrazole, imidazole or triazole ring
- R 1 and R 2 which are the same or different, are H, OH, halogen, C 1 -C 4 alkoxy, C 1 -C 4 alkyl, nitro, amino, cyano, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, carboxy or carboxamido; or the OH group, together with one of R 1 or R 2 , or R 1 and R 2 , can form a methylenedioxy group —O—CH 2 —O—; and
- n is an integer from 0-4.
- Preferred compounds of formula III are those wherein A is pyrazolo[4,3-e] or 1,2,3-triazolo[5,4-e].
- U.S. Pat. No. 5,565,460 discloses useful adenosine A 2a receptor antagonist compounds having the structural formulas IVA and IVB, wherein formula IVA is
- R 1 represents hydrogen, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower alkanoyl
- R 2 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heterocyclic group;
- R 3 represents a substituted or unsubstituted heterocyclic group
- X represents a single bond, O, S, S(O), S(O) 2 , or NR 4 (in which R 4 represents hydrogen, or substituted or unsubstituted lower alkyl; or R 2 and NR 4 are combined to form a substituted or unsubstituted 4 to 6-membered saturated heterocyclic group): and
- A represents N or CR 5 (in which R 5 represents hydrogen, or a substituted or unsubstituted lower alkyl);
- R 6 represents substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group
- Y represents O, S, or NR 7 (in which R 7 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl);
- R 8 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heterocyclic group;
- B and the adjacent two carbon atoms are combined to form a substituted or unsubstituted, partially saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic group.
- WO 03/032996 discloses useful adenosine A 2a receptor antagonist compounds having the structural formula V
- R is R 1 -heteroaryl, R 10 -phenyl, C 4 -C 6 cycloalkenyl, ⁇ ( ⁇ CH 2 )CH 3 , —C ⁇ C—CH 3 , —C ⁇ C—CH 2 —OR 2 , —CH ⁇ C(CH 3 ) 2 ,
- X is C 1 -C 6 alkylene, —C(O)CH 2 — or —C(O)N(R 2 )CH 2 —;
- Y is —N(R 2 )CH 2 CH 2 N(R 3)—, —OCH 2 CH 2 N(R 2 )—, —O—, —S—, —CH 2 S—, —(CH 2 ) 2-3 —N(R 2 )—, R 5 -divalent heteroaryl,
- Z is R 5 -phenyl, R 5 -phenyl(C 1 -C 6 )alkyl, R 5 -heteroaryl, R 5 -bicyclic heteroaryl, R 5 -benzofused heteroaryl, diphenylmethyl or R 6 —C(O)—; or when Y is
- Z is also R 6 —SO 2 —, R 7 —N(R 8 )—C(O)—, R 7 —N(R 8 )—C(S)— or R 6 OC(O)—; or when Q is
- Z is also phenylamino or pyridylamino; or Z and Y together are
- Y and Z together form a piperidinyl or pyrrolidinyl ring fused to a monocyclic or bicyclic aryl or a monocyclic or bicyclic heteroaryl ring wherein X is attached to the N atom of the piperidinyl or pyrrolidinyl ring;
- R 1 is 1 to 3 substituents independently selected from hydrogen, C 1 -C 6 -alkyl, —CF 3 , halogen, —NO 2 , —NR 12 R 13 , C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, —COOR 7 or —C(O)NR 2 R 3 ;
- R 2 and R 3 are independently selected from the group consisting of hydrogen and C 1 -C 6 alkyl
- p and q are independently 0-2;
- Q and Q 1 are independently selected from the group consisting of
- R 4 is 1-2 substituents independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, R 1 -aryl and R 1 -heteroaryl, or two R 4 substituents on the same carbon can form ⁇ O;
- R 5 is 1 to 5 substituents independently selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, —CN, di-((C 1 -C 6 )alkyl)amino, —CF 3 , —OCF 3 , acetyl, —NO 2 , hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )-alkoxy(C 1 -C 6 )alkoxy, di-((C 1 -C 6 )-alkoxy)(C 1 -C 6 )alkoxy, (C 1 -C 6 )-alkoxy(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, carboxy(C 1 -C 6 )-alkoxy, (C 1 -C 6 )-alkoxycarbonyl(C 1 -C 6 )alkoxy, (C 3
- R 6 is (C 1 -C 6 )alkyl, R 5 -phenyl, R 5 -phenyl(C 1 -C 6 )alkyl, thienyl, pyridyl, (C 3 -C 6 )-cycloalkyl, (C 1 -C 6 )alkyl-OC(O)NH—(C 1 -C 6 )alkyl-, di-((C 1 -C 6 )alkyl)aminomethyl, or
- R 7 is (C 1 -C 6 )alkyl, R 5 -phenyl or R 5 -phenyl(C 1 -C 6 )alkyl;
- R 8 is hydrogen or C 1 -C 6 alkyl; or R 7 and R 8 together are —(CH 2 ) p A-(CH 2 ) q , wherein p and q are independently 2 or 3 and A is a bond, —CH 2 —, —S— or —O—, and form a ring with the nitrogen to which they are attached;
- R 9 is 1-2 substituents independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, halogen, —CF 3 and (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy;
- R 10 is 1 to 5 substituents independently selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, —CN, —NH 2 , C 1 -C 6 alkylamino, di-((C 1 -C 6 )alkyl)amino, —CF 3 , —OCF 3 , —S(O) 0-2 (C 1 -C 6 )alkyl and —CH 2 —SO 2 -phenyl;
- R 11 is H, C 1 -C 6 alkyl, phenyl, benzyl, C 2 -C 6 alkenyl, C 1 -C 8 alkoxy(C 1 -C 6 )alkyl, di-((C 1 -C 6 )alkyl)amino(C 1 -C 6 )alkyl, pyrrolidinyl(C 1 -C 6 )alkyl or piperidino(C 1 -C 6 )alkyl;
- R 12 is H or C 1 -C 6 alkyl
- R 13 is H, (C 1 -C 6 )alkyl-C(O)— or (C 1 -C 6 )alkyl-SO 2 —;
- R 14 is H, halogen, C 1 -C 6 alkyl, hydroxy(C 1 -C 6 )alkyl, C 1 -C 6 alkoxy(C 1 -C 6 )alkyl, thio(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylthio(C 1 -C 6 )alkyl or NR 2 R 3 —(C 1 -C 6 )alkyl; and
- R 15 is H, halogen, C 1 -C 6 alkyl or C 1 -C 6 alkoxy.
- Preferred compounds of formula V are those wherein R is R 1 -furanyl, R 1 -thienyl, R 1 -pyrrolyl, R 1 -pyridyl or R 10 -phenyl, more preferably R 1 -furanyl or R 10 -phenyl.
- R 1 is preferably hydrogen or halogen.
- R 10 is preferably hydrogen, halogen, alkyl or —CF 3 .
- Another group of preferred compounds is that wherein X is alkylene, preferably ethylene. Y is preferably
- R 4 is H.
- a preferred definition for Z is R 5 -phenyl or R 5 -heteroaryl.
- R 5 is preferably H, halogen, alkyl, alkoxy, hydroxyalkoxy or alkoxyalkoxy.
- R 6 is preferably R 5 -phenyl.
- Preferred specific compounds of formula V are those of the formula VA
- R and Z-Y are as defined in the following table:
- WO 03/048165 discloses useful adenosine A 2a receptor antagonist compounds having the structural formula VI
- R is selected from the group consisting of R 1 -furanyl-, R 1 -thienyl-, R 1 -pyridyl-, R 1 oxazolyl-, R 1 -pyrrolyl- and R 2 -aryl-;
- X is —(CH 2 ) n —;
- Y is a piperidinyl, pyrrolidinyl or azepanyl group with an aryl or heteroaryl moiety fused to two adjacent carbon atoms on Y, wherein X is attached to the N atom of the piperidinyl, pyrrolidinyl or azepanyl group;
- Q is 1-4 substituents, which can be the same or different, and are independently selected from the group consisting of hydrogen, cycloalkyl, cycloheteroalkyl, amino, aryl, aralkyl, heteroaryl, alkyl, CF 3 , CN, halogen, NO 2 , alkoxy, alkoxyalkoxy, cycloalkylalkoxy, acyloxy, alkylamino, acylamino, alkylsulfonamino, alkylaminosulfonyl, dialkylaminosulfonyl, NH 2 SO 2 —, and hydroxy;
- n 1 to 4.
- R 1 is 1-3 substituents, which may be the same or different, and are independently selected from the group consisting of hydrogen, alkyl, CF 3 , halogen and NO 2 ;
- R 2 is 1-3 substituents, which may be the same or different, and are independently selected from the group consisting of hydrogen, alkyl, CF 3 , halogen, NO 2 , alkoxy, acyloxy, alkylamino, acylamino, alkylsulfonamido, alkylaminosulfonyl, dialkylaminosulfonyl, aminosulfonyl, and hydroxyl.
- a 1 is N—X
- a 2 and A 3 each are CR 4 R 5 , or
- a 4 is CR 4 R 5 ;
- Z 1 , Z 2 , Z 3 and Z 4 which can the same or different, are each independently selected from the group consisting of N and CR 3 , provided that 0-2 of Z 1 , Z 2 , Z 3 or Z 4 are N and the remainder are CR 3 ;
- Z 5 is NR 5 , O, S or CR 4 R 5 ;
- Z 6 is N or CR 3 ;
- Z 7 is N or CR 3 ;
- n is an integer from 0 to 2;
- R 3 is selected from the group consisting of hydrogen, cycloalkyl, amino, aryl, heteroaryl, C 1 -C 6 -alkyl, CF 3 , CN, halogen, NO 2 , C 1 -C 6 -alkoxy, C 1 -C 6 -acyloxy, C 1 -C 6 -alkylamino, C 1 -C 6 -acylamino, C 1 -C 6 -alkylsulfonamino, C 1 -C 6 -alkylaminosulfonyl, C 1 -C 6 -dialkylaminosulfonyl, NH 2 —SO 2 —, and hydroxy;
- R 4 is selected from the group consisting of hydrogen, hydroxyalkyl, aryl, aralkyl, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, CF 3 , CN, halogen, hydroxy, and NO 2 ;
- R 5 is hydrogen or C 1 -C 6 alkyl.
- Preferred specific examples of compounds of formula VI include compounds of the formula:
- WO 03/048164 discloses useful adenosine A 2a receptor antagonist compounds having the structural formula VII
- R is selected from the group consisting of R 4 -heteroaryl, R 5 -phenyl, (C 4 -C 6 )cycloalkenyl, —C( ⁇ CH 2 )CH 3 , —C ⁇ C—CH 3 ,
- R 2 is selected from the group consisting of —W—X, —NR 19 (CH 2 ) m —W—X, and —NR 19 CH(CH 3 )—W—X, or
- R 2 is selected from the group consisting of alkyl, alkenyl and —NR 18 R 19 , wherein said alkyl, alkenyl or —NR 18 R 19 is optionally substituted by —W—X;
- R 3 is selected from the group consisting of H, halo, alkyl, trifluoromethyl, alkoxy, alkoxyalkyl, hydroxyalkyl, alkylamino, alkylaminoalkyl, dialkylamino, dialkylaminoalkyl, aminoalkyl, aryl, heteroaryl, and CN;
- R 4 is 1 to 3 substituents, which can be the same or different, and are independently selected from the group consisting of hydrogen, (C 1 -C 6 )-alkyl, —CF 3 , halogen, —NO 2 , —NR 15 R 16 , (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylsulfinyl, (C 1 -C 6 )alkylsulfonyl, —COOR 17 and —C(O)NR 6 R 7 ;
- R 5 is 1 to 5 substituents, which can be the same or different, and are independently selected from the group consisting of hydrogen, halogen, (C 1 -C 6 )alkyl, hydroxy, (C 1 -C 6 )alkoxy, —CN, —NH 2 , (C 1 -C 6 )alkylamino, di-((C 1 -C 6 )alkyl)amino, —CF 3 , —OCF 3 , —S(O) 0-2 (C 1 -C 6 )alkyl and —CH 2 —SO 2 -phenyl;
- R 6 and R 7 which can be the same or different, are each independently selected from the group consisting of hydrogen and (C 1 -C 6 )alkyl;
- R 8 is 1 to 5 substituents, which can be the same or different, and are independently selected from the group consisting of hydrogen, halogen, (C 1 -C 6 )alkyl, hydroxy, C 1 -C 6 alkoxy, —CN, amino, di-((C 1 -C 6 )alkyl)amino, —CF 3 , —OCF 3 , acetyl, —NO 2 , hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )-alkoxy(C 1 -C 6 )alkoxy, di-((C 1 -C 6 )-alkoxy)(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkoxy-(C 1 -C 6 )-alkoxy, carboxy(C 1 -C 6 )-alkoxy, (C 1 -C 6 )alkoxycarbonyl(C
- R 8 substituents together are —O—CH 2 —O—, —O—CH 2 CH 2 —O—, —O—CF 2 —O—or
- R 9 is selected from the group consisting of (C 1 -C 6 )alkyl, R 8 -aryl-, R 8 -aryl(C 1 -C 6 )alkyl-, thienyl, pyridyl, (C 3 -C 6 )-cycloalkyl, (C 1 -C 6 )alkyl-OC(O)—NH—(C 1 -C 6 )alkyl-, di-((C 1 -C 6 )alkyl)aminomethyl, cycloheteroalkyl(C 1 -C 6 )alkyl, aryloxy(C 1 -C 6 )alkyl, alkoxy(C 1 -C 6 )alkyl and
- R 10 is 1-2 substituents, which can be the same or different, and are independently selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl, R 5 -aryl and R 4 -heteroaryl, or two R 10 substituents on the same carbon can form ⁇ O;
- R 11 is hydrogen or (C 1 -C 6 )alkyl; —C(O)alkyl, or R 17 and R 11 taken together are —(CH 2 ) p -A-(CH 2 ) q , wherein p and q are each independently 2 or 3 and A is selected from the group consisting of a bond, —CH 2 —, —S— and —O—, and form a ring with the nitrogen to which they are attached;
- R 12 is 1-2 substituents, which can be the same or different, and are independently selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl, hydroxy, (C 1 -C 6 )alkoxy, halogen, and —CF 3 ;
- R 13 is selected from the group consisting of H, (C 1 -C 6 )alkyl, phenyl, benzyl, (C 2 -C 6 )alkenyl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, di-((C 1 -C 6 )alkyl)amino(C 1 -C 6 )alkyl, pyrrolidinyl(C 1 -C 6 )alkyl and piperidino(C 1 -C 6 )alkyl;
- R 14 is selected from the group consisting of H, halogen, (C 1 -C 6 )alkyl or (C 1 -C 6 )alkoxy;
- R 15 is selected from the group consisting of H and (C 1 -C 6 )alkyl
- R 16 is selected from the group consisting of H, (C 1 -C 6 )alkyl-C(O)— and (C 1 -C 6 )alkyl-SO 2 —;
- R 17 is selected from the group consisting of (C 1 -C 6 )alkyl, (C 1 -C 6 )hydroxyalkyl, (C 3 -C 6 )cycloalkyl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, allyl, propargyl, R 8 -heteroaryl-, R 8 -aryl- and R 8 -aryl(C 1 -C 6 )alkyl-;
- R 18 is selected from the group consisting of a bond, —CH 2 —, —CH(OH)—, —CH(CH 3 )—, —C(CH 3 ) n —, —(CH 2 ) n —, and —O(CH 2 ) n —,
- R 19 is selected from the group consisting of H, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl(C 1 -C 6 )cycloalkyl, (C 1 -C 6 )cycloalkyl(C 1 -C 6 )alkyl and (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl;
- Q and Q 1 can be the same or different and are each independently selected from the group consisting of
- n are each independently 1-3;
- p and q are each independently 0-2;
- s 0-4;
- W is aryl or heteroaryl having 1-3 heteroatoms, which can be the same or different, and are independently selected from the group consisting of N, O and S, and wherein said aryl or heteroaryl is optionally substituted with 1-3 substituents, which can be the same or different, and are independently selected from the group consisting of alkyl, aryl, alkylcycloalkyl, halo, hydroxy, hydroxyalkyl, alkoxy, alkylalkoxy, alkoxyalkoxy, —NR 6 R 7 , (C 2 -C 6 )alkene, and —CN, or
- X is selected from the group consisting of H, NH 2 , —N(R 6 )(CH 2 ) s -aryl, —N(R 6 )(CH 2 ) s -heteroaryl, —N(R 6 )(CH 2 ) m+1 —OH, and —N(CH 3 ) 2 , or
- X is —R 18 —Y-Z
- Y is selected from the group consisting of —N(R 6 )CH 2 CH 2 N(R 7 )—, —N(R 6 )(CH 2 ) n aryl, —OCH 2 CH 2 N(R 6 )—, —O—, —S—, —CH 2 S—, —(CH 2 ) 2-3 —N(R 6 )—, R 8 -divalent heteroaryl,
- Z is selected from the group consisting of H, alkyl, alkoxyalkyl, R 8 -aryl-, R 8 -aryl(C 1 -C 6 )alkyl-, R 8 -heteroaryl-, R 8 -bicyclicalkyl-, aminoalkyl, alkylamino, NH 2 , —N—(R 6 )(CH 2 ) s -aryl, —N(R 6 )(CH 2 ) s -heteroaryl, —N(R 6 )C(O)OR 17 , alkylcycloheteroalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, alkoxycycloheteroalkyl, heteroaryl; R 8 -benzofused heteroaryl-, diphenylmethyl and R 9 —C(O)—; or
- Z can also be —OH, R 9 —SO 2 —, R 17 —N(R 11 )(CH 2 ) s —C(O), R 17 —OC(O)—, R 17 —O(CH 2 ) n C(O)—, benzofused heteroaryl(CH 2 ) n C(O)—, benzofused heteroaryl(CH 2 ) n — or R 17 —N(R 11 )—C(S)—; or
- Z can also be R 17 R 11 N—, phenylamino or pyridylamino; or
- Preferred compounds of formula VII are those having the following structures:
- WO 03/048163 discloses useful adenosine A 2a receptor antagonist compounds having the structural formula VII
- A is C(R 1 ) or N;
- R 1 and R 1a are independently selected from the group consisting of H, (C 1 -C 6 )-alkyl, halo, CN and —CF 3 ;
- Y is —O—, —S—, —SO—, —SO 2 —, R 5 -heteroaryldiyl, R 5 -arylene or
- Q and Q 1 are independently selected from the group consisting of
- R is R 5- aryl, R 5- heteroaryl, R 6 —(C 2 -C 6 )alkenyl or R 6 —(C 2 -C 6 )alkynyl;
- R 2 is R 5- aryl, R 5- heteroaryl, R 5- aryl(C 1 -C 6 )alkyl or R 5- heteroaryl(C 1 -C 6 )alkyl; or R 2 —Y is
- U, V, and W are independently selected from the group consisting of N and CR 1 , provided that at least one of U, V and W is CR 1 ;
- n 1, 2 or 3;
- n 2 or 3;
- n 0
- R 3 and R 3a are independently selected from the group consisting of H, —OH, C 1 -C 6 alkyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, amino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl and di(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl;
- R 4 is 1-3 substituents selected from the group consisting of H, (C 1 -C 6 )alkyl, —OH, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkoxy, halo, —CF 3 , and —CN;
- R 5 is 1-3 substituents independently selected from the group consisting of H, (C 1 -C 6 )alkyl, —OH, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkoxy, halo, —CF 3 , —CN, —NH 2 , (C 1 -C 6 )alkylamino, di(C 1 -C 6 )alkylamino, amino(C 1 -C 6 )-alkyl, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, di(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkanoyl-amino, (C 1 -C 6 )alkanesulfon
- R 6 (C 2 -C 6 )alkenyl, R 6 —(C 2 -C 6 )alkynyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-C(O)-amino, or heterocycloalkyl(C 1 -C 6 )alkyl;
- R 6 is 1 to 3 substituents independently selected from the group consisting of H, —OH, (C 1 -C 6 )alkoxy and halo;
- R 7 and R 7a are independently selected from the group consisting of H, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, R 8 -aryl and R 8 -heteroaryl, or an R 7 and an R 7a substituent on the same carbon can form ⁇ O;
- R 8 is 1 to 3 substituents independently selected from H, (C 1 -C 6 )alkyl, —OH, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkoxy, halo, —CF 3 , and —CN;
- R 9 and R 9a are independently selected from the group consisting of H, (C 1 -C 6 )alkyl, hydroxy(C 2 -C 6 )alkyl, (C 1 -C 6 )alkoxy(C 2 -C 6 )alkyl, amino(C 2 -C 6 )alkyl, (C 1 -C 6 )alkylamino(C 2 -C 6 )alkyl, di(C 1 -C 6 )alkylamino(C 2 -C 6 )alkyl, halo-(C 3 -C 6 )alkenyl, CF 3 —(C 1 -C 6 )alkyl, (C 3 -C 6 )alkenyl, (C 3 -C 6 )cycloalkyl and (C 3 -C 6 )cycloalkyl-(C 1 -C 6 )alkyl; and
- R 10 is H, —C(O)—O—(C 1 -C 6 )alkyl, R 5 -aryl, —C(O)—(C 1 -C 6 )alkyl, —C(O)—(R 5 -aryl) or R 5 -aryl-(C 1 -C 6 )alkyl.
- Preferred compounds of formula VIII are those wherein A is N.
- R is preferably furyl.
- R 1a is preferably hydrogen.
- Another group of preferred compounds is that wherein X is —O—, —S—, —N(R 9 )— or R 4 -arylene, with compounds wherein X is —N(R 9 )— being more preferred.
- R 9 is preferably C 1 -C 6 alkyl.
- Preferred definitions for Y are a bond or piperazinyl.
- R 2 is preferably R 5 -aryl. When Y and/or R 2 is
- Q is preferably N, Q 1 is preferably N, p and q are each preferably 2, each R 7 and R 7a is preferably hydrogen, and R 10 is preferably —C(O)—O—(C 1 -C 6 )alkyl, —C(O)—(C 1 -C 6 )alkyl or —C(O)—(R 5 -aryl).
- R 5 is preferably 1 or 2 substituents selected from the group consisting of H, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy(C 1 -C 6 )-alkoxy, halo and —CF 3 .
- R 4 is preferably H, halo or (C 1 -C 6 )alkyl.
- R 3 and R 3a are preferably independently selected from H and (C 1 -C 6 )alkyl.
- R 9a is preferably H or (C 1 -C 6 )alkyl.
- R 6 is preferably
- R 2 —Y—(CH 2 ) n —N(R 9 )— is as defined in the table:
- WO 01/02409 discloses useful adenosine A 2a receptor antagonist compounds having the structural formula IX
- X is O or S
- R 1 and R 2 are independently selected from hydrogen, alkyl, aryl, hydroxy, alkoky, aryloxy, cyano, nitro, CO 2 R 7 , COR 7 , OCOR 7 , CONR 7 R 8 , CONR 7 NR 8 R 9 , OCONR 7 R 8 , NR 7 R 8 , NR 7 COR 8 , NR 7 CONR 8 R 9 , NR 7 CO 2 R 8 , NR 7 SO 2 R 8 , NR 7 CONR 8 NR 9 R 10 , NR 7 NR 8 CO 2 R 9 , NR 7 NR 8 CONR 9 R 10 , NR 7 SO 2 NR 8 R 9 , SO 2 R 7 , SOR 7 , SR 7 and SO 2 NR 7 R 8 , or R 1 and R 2 together form a carbonyl group (C ⁇ O), an oxime group (C ⁇ NOR 11 ), an imine group (C ⁇ NR 1 ) or a hydrazine group (C ⁇ NNR
- R 3 is alkyl or aryl
- R 4 , R 5 and R 6 ate independently selected from hydrogen, alkyl, aryl, halogen, hydroxy, nitro, cyano, alkoxy, aryloxy, CO 2 R 7 , COR 7 , OCOR 7 , SO 2 R 7 , SOR 7 , SR 7 , SO 2 NR 7 R 8 , CONR 7 R 8 , CONR 7 NR 8 R 9 , OCONR 7 R 8 , NR 7 R 8 , NR 7 COR 8 , NR 7 CONR 8 R 9 , NR 7 CO 2 R 8 , NR 7 SO 2 R 8 , CR 7 ⁇ NOR 8 , NR 7 CONR 8 NR 9 R 10 , NR 7 NR 8 CO 2 R 9 , NR 7 NR 8 CONR 9 R 10 , SO 2 NR 7 NR 8 R 9 , NR 7 SO 2 NR 8 R 9 , NR 7 NR 8 SO 2 R 9 , NR 7 NR 8 CO 2 R 9 , NR
- R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are independently selected from hydrogen, alkyl and aryl, or a pharmaceutically acceptable salt or prodrug thereof.
- patient means a mammal, especially a human.
- adenosine A 2a receptor antagonist e.g., 2 or 3
- adenosine A 2a receptor antagonist e.g., 2 or 3
- one adenosine A 2a receptor antagonist is administered.
- Antipsychotic agents causing the EPS treated by adenosine A 2a receptor antagonists and for use in combination with adenosine A 2a receptor antagonists include typical and atypical antipsychotic agents.
- Typical antipsychotics include loxapine, haloperidol, chlorpromazine, prochlorperazine and thiothixene.
- Atypical antipsychotics include clozapine, olanzapine, loxapine, quetiapine, ziprasidone and risperidone.
- Tricyclic antidepressants causing dystonia treated by adenosine A 2a receptor antagonists include perphenazine, amitriptyline, desipramine, doxepin, trimipramine and protriptyline.
- Anticonvulsants which may cause dystonia, but which also may be useful in treating ERLS or PLMS include phenyloin, carbamazepine and gabapentin.
- Dopamine agonists useful in treating RLS and PLMS include pergolide, pramipexole, ropinerole, fenoldopam and cabergoline.
- Opioids useful in treating PRLS and PLMS include codeine, hydrocodone, oxycodone, propoxyphene and tramadol.
- Benzodiazepines useful in treating PRLS and PLMS include clonazepam, triazolam and temazepam.
- antipsychotics tricyclic antidepressants, anticonvulsants, dopamine agonists, opioids and benzodiazepines are commercially available and are described in the literature, e.g., in The Physicians' Desk Reference (Montvale: Medical Economics Co., Inc., 2001).
- a 2a receptor antagonists could be administered in combination with one or more other agents (e.g., antipsychotics, tricyclic antidepressants, anticonvulsants, dopamine agonists, opioids or benzodiazepines), although administration of one A 2a antagonist in combination with one other agent is preferred for each of the indications. While administration of separate dosage forms of the A 2a antagonist(s) and the other agent(s) are preferred, it is also contemplated that the other agent(s) could be combined in a single dosage form with the A 2a receptor antagonist(s) for the treatment or prevention of EPS, dystonia, RLS or PLMS.
- agents e.g., antipsychotics, tricyclic antidepressants, anticonvulsants, dopamine agonists, opioids or benzodiazepines
- Preferred adenosine A 2a antagonists are those described in U.S. Pat. No. 6,630,475.
- a particularly preferred compound of the invention is Compound A of the formula
- Membrane sources A 2a : Human A 2a Adenosine Receptor membranes, Catalog #RB-HA2a, Receptor Biology, Inc., Beltsville, Md. Dilute to 17 ⁇ g/100 ⁇ l in membrane dilution buffer (see below).
- Assay Buffers Membrane dilution buffer: Dulbecco's Phosphate Buffered Saline (Gibco/BRL)+10 mM MgCl 2 .
- Compound Dilution Buffer Dulbecco's Phosphate Buffered Saline (Gibco/BRL)+10 mM MgCl 2 supplemented with 1.6 mg/ml methyl cellulose and 16% DMSO. Prepared fresh daily.
- Ligands A 2a : [3H]-SCH 58261, custom synthesis, AmershamPharmacia Biotech, Piscataway, N.J. Stock is prepared at 1 nM in membrane dilution buffer. Final assay concentration is 0.5 nM.
- a 1 [3H]-DPCPX, AmershamPharmacia Biotech, Piscataway, N.J. Stock is prepared at 2 nM in membrane dilution buffer. Final assay concentration is 1 nM.
- a 2a To determine non-specific binding, add 100 nM CGS 15923 (RBI, Natick, Mass.). Working stock is prepared at 400 nM in compound dilution buffer.
- a 1 To determine non-specific binding, add 100 ⁇ M NECA (RBI, Natick, Mass.). Working stock is prepared at 400 ⁇ M in compound dilution buffer.
- Total assay volume is 200 ⁇ l.
- mice Male Sprague-Dawley rats (Charles River, Calco, Italy) weighing 175-200 g are used.
- the cataleptic state is induced by the subcutaneous administration of the dopamine receptor antagonist haloperidol (1 mg/kg, sc), 90 min before testing the animals on the vertical grid test.
- the rats are placed on the wire mesh cover of a 25 ⁇ 43 plexiglas cage placed at an angle of about 70 degrees with the bench table.
- the rat is placed on the grid with all four legs abducted and extended (“frog posture”).
- the use of such an unnatural posture is essential for the specificity of this test for catalepsy.
- the time span from placement of the paws until the first complete removal of one paw (descent latency) is measured maximally for 120 sec.
- the selective A 2a adenosine antagonists under evaluation are administered orally at doses ranging between 0.03 and 3 mg/kg, 1 and 4 h before scoring the animals.
- inert, pharmaceutically acceptable carriers can be either solid or liquid.
- Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.
- the powders and tablets may be comprised of from about 0.1 to about 99 percent active ingredient.
- Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar, lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.
- a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
- Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection.
- Liquid form preparations may also include solutions for intranasal administration.
- Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas.
- a pharmaceutically acceptable carrier such as an inert compressed gas.
- solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration.
- liquid forms include solutions, suspensions and emulsions.
- the compounds useful in the method of the invention may also be deliverable transdermally.
- the transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
- the adenosine A 2a receptor antagonist and the antipsychotic are administered orally.
- the pharmaceutical preparation is in unit dosage form.
- the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
- the quantity of adenosine A 2a receptor antagonist in a unit dose of preparation may be varied or adjusted from about 0.1 mg to 1000 mg, more preferably from about 1 mg to 300 mg, according to the particular application.
- the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
- a typical recommended dosage regimen for an adenosine A 2a receptor antagonist is oral administration of about 10 mg to 2000 mg/day preferably 10 to 1000 mg/day, in two to four divided doses to provide relief from the effects of EPS, dystonia, RLS or PLMS.
- the compounds are non-toxic when administered within this dosage range.
- the doses and dosage regimen of the other agents used in combination with the adenosine A 2a receptor antagonists i.e., the antipsychotics, tricyclcic antidepressants, anticonvulsants, dopamine agonists, benzodiazepines, opioids, lithium or iron, will be determined by the attending clinician in view of the approved doses and dosage regimen in the package insert, taking into consideration the age, sex and condition of the patient and the severity of the disease.
- the adenosine A 2a receptor antagonist and the other agent can be administered simultaneously or sequentially.
- the components of the combination are preferably given on different dosing schedules, e.g., one component is administered daily and the other every six hours, or when the preferred pharmaceutical compositions are different, e.g. one is preferably a tablet and one is a capsule.
- adenosine A 2a receptor antagonist and the other agent in a kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat or prevent EPS, dystonia, RLS or PLMS, wherein one container comprises a pharmaceutical composition comprising an effective amount of an adenosine A 2a receptor antagonist in a pharmaceutically acceptable carrier, and wherein a separate container comprises a pharmaceutical composition comprising an effective amount of another agent appropriate to treat the indicated condition.
- a dosage form for one of the components of the combination can be modified to contain both an adenosine A 2a receptor antagonist and another agent, e.g., an adenosine A 2a receptor antagonist and an antipsychotic or an adenosine A 2a receptor antagonist and a dopamine agonist.
- another agent e.g., an adenosine A 2a receptor antagonist and an antipsychotic or an adenosine A 2a receptor antagonist and a dopamine agonist.
- EPS Extra-Pyramidal Syndrome
- Compound A was administered orally (p.o.) at doses of 0.3-30 mg/kg, in conjunction with haloperidol.
- the studies were conducted using a within-subjects design such that each monkey received all 6 treatments (vehicle and 5 doses of Compound A) in a crossover, balanced design. In all the studies, the group of seven monkeys exhibited baseline levels of EPS when dosed with haloperidol.
- Compound A produced a dose-dependent reduction in the maximum EPS score ( FIG. 1A ), as well as a dose-dependent delay in the onset of EPS ( FIG. 1B ).
- Compound A prevented the onset of EPS in one monkey, and delayed the onset of EPS by 1 hr.
- Compound A at a dose of 3 mg/kg, prevented the onset of EPS in two monkeys, and delayed the onset of EPS by almost 2 hr in the remaining monkeys.
- Compound A prevented the onset of EPS in three monkeys and delayed the onset of EPS by an average of 2.3-2.9 hr.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
There is disclosed a method for the treatment or prevention of Extra Pyramidal syndrome (EPS), dystonia, restless leg syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating EPS, dystonia, RLS or PLMS.
Description
- This application claims the benefit of U.S. Provisional Application 60/435,321, filed Dec. 19, 2002.
- The present invention relates to the use of adenosine A2a receptor antagonists for the treatment of a variety of neurological syndromes involving the extra-pyramidal motor system (i.e. Extra-Pyramidal Syndrome) that occur following the acute and chronic use of almost all antipsychotic drugs. The invention also relates to the use of adenosine A2a receptor antagonists for the treatment of other abnormal movement disorders such as restless leg syndrome (RLS) and periodic limb movement in sleep (PLMS).
- Extra-Pyramidal Syndrome (EPS) is a collective term for a series of adverse neurological reactions associated with the use of antipsychotic drugs. There are six different categories of EPS-related neurological syndromes of which four, dystonia, akathisia, pseudoparkinsonism (parkinsonian syndrome), and tardive dyskinesia, are particularly prevalent in patients taking antipsychotic medication. Dystonia is a painful spasm of the muscle groups of, in particular, the neck, jaw, back, pharynx, and larynx. It is most common in young males being treated with antipsychotic drugs, but can also be associated with the use of cocaine, tricyclic antidepressants, lithium and anticonvulsants such as phenyloin and carbamazepine. Pseudoparkinsonism manifests itself as akinesia (rigidity, stiffness and slow voluntary motion, stooped, shuffling walk) and tremor and these symptoms develop within weeks or months after initiation of therapy. Akathisia manifests itself as strong, subjective inner feelings of distress or discomfort characterized by motor restlessness. Often mistaken for agitation or anxiety, this common syndrome is frequently under-diagnosed and is the least responsive to treatment. Tardive dyskinesia is a late-appearing syndrome associated with chronic use of neuroleptic drugs. It occurs more frequently in older patients and is characterized by stereotypical, repetitive, involuntary, quick choreiform movements of the face, eyelids, mouth, tongue, extremities and trunk.
- EPS is more prevalent with the use of typical antipsychotic agents but has also been reported with the use of atypical agents. Typical antipsychotics include loxapine, haloperidol, chlorpromazine, prochlorperazine and thiothixene. Atypical antipsychotics include clozapine, olanzapine, loxapine, quetiapine, ziprasidone and risperidone.
- Akathisia is also a characteristic of RLS and PLMS, as well as PLMD (periodic leg (or limb) movement disorder). RLS is a common disorder that causes patients to have an irresistible and unpleasant desire to move their legs; it usually manifests during periods of inactivity and/or at night, and can disturb sleep. Patients who do not have the typical RLS symptoms, but who do exhibit periodic leg movements that adversely impact sleep, are diagnosed with PLMS. Treatments for RLS and PLMS have included levodopa/carbidopa, levodopa/benserazide, dopamine agonists such as pramipexole and ropinerole, benzodiazepines, opioids, anticonvulsants and iron (ferrous sulfate). RLS and PLMS have been extensively described in the literature, for example by Saletu et al, Neuropsvchobiology, 41, 4 (2000), p. 190-9.
- The purine nucleotide, adenosine, is known to be an endogenous modulator of a number of physiological functions in the central (CNS) and peripheral nervous systems.
- Adenosine exerts its biological actions through a class of membrane specific receptors which belong to the super family of receptors coupled with G proteins. Biochemical and pharmacological studies, together with advances in molecular biology, have allowed the identification of at least four subtypes of adenosine receptors: A1, A2a, A2b and A3. Analogs of adenosine able to interact as antagonists with the A1, A2a, A2b and A3 receptors have also been identified.
- In the CNS, data has shown that A2a receptors are present in high density in the basal ganglia, known to be important in the control of fine motor movement. Moreover, selective antagonists for the A2a receptor are of pharmacological interest because of their demonstrated efficacy in reducing motor impairment thereby improving function in neurodegenerative diseases such as Parkinson's disease and related movement disorders (e.g. Huntington's Disease). A2a antagonists appear to demonstrate a reduced side-effect liability (e.g. no dyskinesia) compared to current dopaminergic therapies resulting in an improved therapeutic index. A2a antagonists may also have antidepressant properties and stimulate cognitive functions. Some xanthine-related compounds have been found to be A1 receptor selective antagonists, and xanthine and non-xanthine compounds have been found to have high A2a affinity with varying decrees of A2a vs. A1 selectivity. Adenosine A2a receptor antagonists have been disclosed previously, for example in WO 95/01356 and U.S. Pat. No. 6,630,475.
- This invention relates to a method for the treatment or prevention of Extra-Pyramidal Syndrome (e.g., dystonia, akathisia, pseudoparkinsonism and tardive dyskinesia) comprising administering a therapeutically effective amount of an adenosine A2a receptor antagonist to a patient in need thereof. In particular, this method is for the treatment or prevention of EPS in patients treated with an antipsychotic agent that has the side effect of inducing EPS. The adenosine A2a receptor antagonist can be administered after the symptoms of EPS have manifested, or an adenosine A2a receptor antagonist can be administered at the onset of administering an antipsychotic agent in order to prevent EPS from occurring. The invention, therefore, also includes a method of treating or preventing EPS induced by an antipsychotic agent comprising administering a combination of an antipsychotic agent and an adenosine A2a antagonist to a patient in need thereof. More particularly, the invention relates to the method of using of certain adenosine A2a antagonists for the monotherapy or the combined therapy.
- The invention also relates to the treatment of primary (idiopathic) dystonia, and to the treatment or prevention of dystonia in patients who exhibit dystonia as a result of treatment with a tricyclic antidepressant, lithium or an anticonvulsant, or who have used cocaine, comprising administering a therapeutically effective amount of an adenosine A2a receptor antagonist to a patient in need thereof. When dystonia is caused by treatment with a tricyclic antidepressant, lithium or an anticonvulsant, the adenosine A2a receptor antagonist can be administered after the symptoms of dystonia have manifested, or an adenosine A2a receptor antagonist can be administered at the onset of administering a tricyclic antidepressant, lithium or an anticonvulsant in order to prevent dystonia from occurring. The invention, therefore, also includes a method of treating or preventing dystonia induced by a tricyclic antidepressant, lithium or an anticonvulsant comprising administering a combination of an adenosine A2a antagonist and a tricyclic antidepressant, lithium or an anticonvulsant to a patient in need thereof.
- The invention also relates to the treatment of RLS or PLMS, comprising administering to a patient in need thereof a therapeutically effective amount of an adenosine A2a receptor antagonist. The invention also comprises a method of treating RLS or PLMS comprising administering a combination of an adenosine A2a antagonist with another agent useful in treating RLS or PLMS, such as levodopa/carbidopa, levodopa/benserazide, a dopamine agonist, a benzodiazepine, an opioid, an anticonvulsant or iron, to a patient in need thereof.
- In another aspect, this invention relates to a kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat or prevent EPS caused by treatment with antipsychotic agent, wherein one container comprises a pharmaceutical composition comprising an effective amount of an adenosine A2a receptor antagonist in a pharmaceutically acceptable carrier, and wherein a separate container comprises a pharmaceutical composition comprising an effective amount of an antipsychotic agent.
- In another aspect, this invention relates to a kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat or prevent dystonia caused by treatment with a tricyclic antidepressant, lithium or an anticonvulsant, wherein one container comprises a pharmaceutical composition comprising an effective amount of an adenosine A2a receptor antagonist in a pharmaceutically acceptable carrier, and wherein a separate container comprises a pharmaceutical composition comprising an effective amount of a tricyclic antidepressant, lithium or an anticonvulsant.
- In another aspect, this invention relates to a kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat RLS or PLMS, wherein one container comprises a pharmaceutical composition comprising an effective amount of an adenosine A2a receptor antagonist in a pharmaceutically acceptable carrier, and wherein a separate container comprises a pharmaceutical composition comprising an effective amount of levodopa/carbidopa, levodopa/benserazide, a dopamine agonist, a benzodiazepine, an opioid, an anticonvulsant or iron.
- The invention also relates to the use of an adenosine A2a receptor antagonist for the preparation of a medicament for treating or preventing EPS, dystonia, RLS or PLMS, alone or in combination with the other agents discussed above.
- A more complete understanding of the invention may be obtained by reading the following description in conjunction with the appended figures relating to haloperidol-induced EPS in Cebus apella monkeys.
-
FIG. 1A illustrates the effect of Compound A (1-30 mg/kg, p.o.) on maximum EPS score. -
FIG. 1B represents the mean delay in onset of EPS for each treatment group compared to a vehicle control group. - Any adenosine A2a receptor antagonist is contemplated for use in the method of this invention. Suitable adenosine A2a receptor antagonists useful in the method of the invention can be identified by the binding assay described below. Specific examples of suitable adenosine A2a antagonists include the compounds disclosed in several patents and patent applications, e.g. WO 95/01356; U.S. Pat. No. 5,565,460; U.S. Pat. No. 6,630,475 B2; U.S. Pat. No. 5,935,964; WO 03/032996; WO 03/048165; WO 03/048164; WO 03/048163; and WO 01/02409. Specifically, these patents and applications disclose the following compounds.
- U.S. Pat. No. 6,630,475 B2 discloses compounds having the structural formula I
- or a pharmaceutically acceptable salt thereof, wherein
- R is R1-furanyl, R1-thienyl, R1-pyridyl, R1-pyridyl N-oxide, R1-oxazolyl, R10-phenyl, R1-pyrrolyl or C4-C6 cycloalkenyl;
- X is C2-C6 alkylene or —C(O)CH2—;
- Y is —N(R2)CH2CH2N(R3)—, —OCH2CH2N(R2)—, —O—, —S—, —CH2S—, —(CH2)2—NH—, or
- and
- Z is R5-phenyl, R5-phenyl(C1-C6)alkyl, R5-heteroaryl, diphenylmethyl, R6—C(O)—,
-
- phenyl-CH(OH)—, or phenyl-C(═NOR2)—; or when Q is
- Z is also phenylamino or pyridylamino;
or - Z and Y together are
- R1 is 1 to 3 substituents independently selected from hydrogen, C1-C6-alkyl, —CF3, halogen, —NO2, —NR12R13, C1-C6 alkoxy, C1-C6 alkylthio, —C6 alkylsulfinyl, and C1-C6 alkylsulfonyl;
- R2 and R3 are independently selected from the group consisting of hydrogen and C1-C6 alkyl;
- m and n are independently 2-3;
- Q is
- R4 is 1-2 substituents independently selected from the group consisting of hydrogen and C1-C6alkyl, or two R4 substituents on the same carbon can form ═O;
- R5 is 1 to 5 substituents independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, —CN, di-((C1-C6)alkyl)amino, —CF3, —OCF3, acetyl, —NO2, hydroxy(C1-C6)alkoxy, (C1-C6)-alkoxy(C1-C6)alkoxy, di-((C1-C6)-alkoxy)(C1-C6)alkoxy, (C1-C6)-alkoxy(C1-C6)alkoxy-(C1-C6)-alkoxy, carboxy(C1-C6)-alkoxy, (C1-C6)-alkoxycarbonyl(C1-C6)alkoxy, (C3-C6)cycloalkyl(C1-C6)alkoxy, di-((C1-C6)alkyl)amino(C1-C6)alkoxy, morpholinyl, (C1-C6)alkyl-SO2—, (C1-C6)alkyl-SO—(C1-C6)alkoxy, tetrahydropyranyloxy, (C1-C6)alkylcarbonyl(C1-C6)-alkoxy, (C1-C6)-alkoxycarbonyl, (C1-C6)alkylcarbonyloxy(C1-C6)-alkoxy, —SO2NH2, phenoxy,
- or adjacent R5 substituents together are —O—CH2—O—, —O—CH2CH2—O—, —O—CF2—O— or —O—CF2CF2—O— and form a ring with the carbon atoms to which they are attached;
- R6 is (C1-C6)alkyl, R5-phenyl, R5-phenyl(C1-C6)alkyl, thienyl, pyridyl, (C3-C6)-cycloalkyl, (C1-C6)alkyl-OC(O)NH—(C1-C6)alkyl-, di-((C1-C6)alkyl)aminomethyl, or
- R7 is (C1-C6)alkyl, R5-phenyl or R5-phenyl(C1-C6)alkyl;
- R8 is hydrogen or C1-C6 alkyl; or R7 and R8 together are —(CH2)p-A-(CH2)q, wherein p and q are independently 2 or 3 and A is a bond, —CH2—, —S— or —O—, and form a ring with the nitrogen to which they are attached;
- R9 is 1-2 groups independently selected from hydrogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halogen, —CF3 and (C1-C6)alkoxy(C1-C6)alkoxy;
- R10 is 1 to 5 substituents independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, —CN, —NH2, C1-C6alkylamino, di-((C1-C6)alkyl)amino, —CF3, —OCF3 and —S(O)0-2(C1-C6)alkyl;
- R11 is H, C1-C6 alkyl, phenyl, benzyl, C2-C6 alkenyl, C1-C6 alkoxy(C1-C6)alkyl, di-((C1-C6)alkyl)amino(C1-C6)alkyl, pyrrolidinyl(C1-C6)alkyl or piperidino(C1-C6)alkyl;
- R12 is H or C1-C6 alkyl; and
- R13 is (C1-C6)alkyl-C(O)— or (C1-C6)alkyl-SO2—.
- Preferred compounds of formula I are those wherein R is R1-furanyl, R1-thienyl, R1-pyrrolyl or R10-phenyl, more preferably R1-furanyl. R1 is preferably hydrogen or halogen. Another group of preferred compounds is that wherein X is alkylene, preferably ethylene. Y is preferably
- wherein Q is
- with Q preferably being nitrogen. Preferably, m and n are each 2, and R4 is H. A preferred definition for Z is R5-phenyl, R5-heteroaryl, R6—C(O)— or R6—SO2—. R5 is preferably H, halogen, alkyl, alkoxy, hydroxyalkoxy or alkoxyalkoxy. R6 is preferably R5-phenyl.
- Preferred specific compounds of formula I are those of the formula IA
- wherein R and Z-Y are as defined in the following table:
- Other useful adenosine A2a receptor antagonists include those disclosed in WO 95/01356 as compounds having the structural formula II
- wherein:
- A is pyrazole, imidazole or a triazole ring;
- R is hydrogen; C1-C8 alkyl; C3-C7 alkenyl; C3-C7 alkynyl; C3-C7 cycloalkyl; C1-C5 alkyl substituted with one or more halogen atoms, hydroxy groups, C1-C4 alkoxy, C3-C7 cycloalkyl, groups of formula —NR1R2, —CONR1R2; aryl optionally substituted with halogen atoms, C1-C4 alkoxy groups, C1-C4 alkyl, nitro, amino, cyano, C1-C4 haloalkyl, C1-C4 haloalkoxy, carboxy, carboxyamido; C7-C10 aralkyl in which the aryl moiety can be substituted with one or more of the substituents indicated above for the aryl group; a group of formula —(CH2)m-Het, wherein Het is a 5-6 membered aromatic or non aromatic heterocyclic ring containing one or more heteroatoms selected from N, O, S and m is an integer from 1 to 5;
- R1, R2 which are the same or different, are hydrogen, C1-C5 alkyl, C7-C10 aralkyl, phenyl, or taken together with the nitrogen they are linked to, form an azetidine ring or a 5-6 membered heterocyclic ring containing one or more heteroatoms such as N, O, S and n is an integer from 2 to 5.
- Preferably, compounds of formula II are those wherein R is hydrogen, C1-C8 alkyl, aryl or C7-C10 aralkyl optionally substituted, preferably with halogen atoms.
- U.S. Pat. No. 5,935,964 discloses useful adenosine A2a receptor antagonist compounds having the structural formula III
- wherein A is pyrazole, imidazole or triazole ring;
- R is
- R1 and R2, which are the same or different, are H, OH, halogen, C1-C4 alkoxy, C1-C4 alkyl, nitro, amino, cyano, C1-C4 haloalkyl, C1-C4 haloalkoxy, carboxy or carboxamido; or the OH group, together with one of R1 or R2, or R1 and R2, can form a methylenedioxy group —O—CH2—O—; and
- n is an integer from 0-4.
- Preferred compounds of formula III are those wherein A is pyrazolo[4,3-e] or 1,2,3-triazolo[5,4-e].
- U.S. Pat. No. 5,565,460 discloses useful adenosine A2a receptor antagonist compounds having the structural formulas IVA and IVB, wherein formula IVA is
- wherein R1 represents hydrogen, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower alkanoyl;
- R2 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heterocyclic group;
- R3 represents a substituted or unsubstituted heterocyclic group;
- X represents a single bond, O, S, S(O), S(O)2, or NR4 (in which R4 represents hydrogen, or substituted or unsubstituted lower alkyl; or R2 and NR4 are combined to form a substituted or unsubstituted 4 to 6-membered saturated heterocyclic group): and
- A represents N or CR5 (in which R5 represents hydrogen, or a substituted or unsubstituted lower alkyl); and
- wherein formula IVB is
- wherein R6 represents substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group;
- Y represents O, S, or NR7 (in which R7 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl);
- R8 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heterocyclic group; and
- B and the adjacent two carbon atoms are combined to form a substituted or unsubstituted, partially saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic group.
- WO 03/032996 discloses useful adenosine A2a receptor antagonist compounds having the structural formula V
- or a pharmaceutically acceptable salt thereof, wherein
- R is R1-heteroaryl, R10-phenyl, C4-C6 cycloalkenyl, <(═CH2)CH3, —C≡C—CH3, —C≡C—CH2—OR2, —CH═C(CH3)2,
- X is C1-C6 alkylene, —C(O)CH2— or —C(O)N(R2)CH2—;
- Y is —N(R2)CH2CH2N(R3)—, —OCH 2CH2N(R2)—, —O—, —S—, —CH2S—, —(CH2)2-3—N(R2)—, R5-divalent heteroaryl,
- and
- Z is R5-phenyl, R5-phenyl(C1-C6)alkyl, R5-heteroaryl, R5-bicyclic heteroaryl, R5-benzofused heteroaryl, diphenylmethyl or R6—C(O)—; or when Y is
- Z is also R6—SO2—, R7—N(R8)—C(O)—, R7—N(R8)—C(S)— or R6OC(O)—; or when Q is
- Z is also phenylamino or pyridylamino;
or Z and Y together are - or Y and Z together form a piperidinyl or pyrrolidinyl ring fused to a monocyclic or bicyclic aryl or a monocyclic or bicyclic heteroaryl ring wherein X is attached to the N atom of the piperidinyl or pyrrolidinyl ring;
- R1 is 1 to 3 substituents independently selected from hydrogen, C1-C6-alkyl, —CF3, halogen, —NO2, —NR12R13, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, —COOR7 or —C(O)NR2R3;
- R2 and R3 are independently selected from the group consisting of hydrogen and C1-C6 alkyl;
- m and n are independently 2-3;
- p and q are independently 0-2;
- Q and Q1 are independently selected from the group consisting of
- provided that at least one of Q and Q1 is
- R4 is 1-2 substituents independently selected from the group consisting of hydrogen, C1-C6alkyl, R1-aryl and R1-heteroaryl, or two R4 substituents on the same carbon can form ═O;
- R5 is 1 to 5 substituents independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, —CN, di-((C1-C6)alkyl)amino, —CF3, —OCF3, acetyl, —NO2, hydroxy(C1-C6)alkoxy, (C1-C6)-alkoxy(C1-C6)alkoxy, di-((C1-C6)-alkoxy)(C1-C6)alkoxy, (C1-C6)-alkoxy(C1-C6)alkoxy-(C1-C6)alkoxy, carboxy(C1-C6)-alkoxy, (C1-C6)-alkoxycarbonyl(C1-C6)alkoxy, (C3-C6)cycloalkyl(C1-C6)alkoxy, di-((C1-C6)alkyl)amino(C1-C6)alkoxy, morpholinyl, (C1-C6)alkyl-SO2—, (C1-C6)alkyl-SO2—(C1-C6)alkoxy, tetrahydropyranyloxy, (C1-C6)alkylcarbonyl(C1-C6)alkoxy, (C1-C6)-alkoxycarbonyl, (C1-C6)alkylcarbonyloxy(C1-C6)-alkoxy, —SO2NH2, phenoxy,
- (R2O)2—P(O)—CH2—O— and (R2O)2—P(O)—; or adjacent R5 substituents together are —O—CH2—O—, —O—CH2CH2—O—, —O—CF2—O— or —O—CF2CF2—O— and form a ring with the carbon atoms to which they are attached;
- R6 is (C1-C6)alkyl, R5-phenyl, R5-phenyl(C1-C6)alkyl, thienyl, pyridyl, (C3-C6)-cycloalkyl, (C1-C6)alkyl-OC(O)NH—(C1-C6)alkyl-, di-((C1-C6)alkyl)aminomethyl, or
- R7 is (C1-C6)alkyl, R5-phenyl or R5-phenyl(C1-C6)alkyl;
- R8 is hydrogen or C1-C6 alkyl; or R7 and R8 together are —(CH2)pA-(CH2)q, wherein p and q are independently 2 or 3 and A is a bond, —CH2—, —S— or —O—, and form a ring with the nitrogen to which they are attached;
- R9 is 1-2 substituents independently selected from the group consisting of hydrogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halogen, —CF3 and (C1-C6)alkoxy-(C1-C6)alkoxy;
- R10 is 1 to 5 substituents independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, —CN, —NH2, C1-C6alkylamino, di-((C1-C6)alkyl)amino, —CF3, —OCF3, —S(O)0-2(C1-C6)alkyl and —CH2—SO2-phenyl;
- R11 is H, C1-C6 alkyl, phenyl, benzyl, C2-C6 alkenyl, C1-C8 alkoxy(C1-C6)alkyl, di-((C1-C6)alkyl)amino(C1-C6)alkyl, pyrrolidinyl(C1-C6)alkyl or piperidino(C1-C6)alkyl;
- R12 is H or C1-C6 alkyl;
- R13 is H, (C1-C6)alkyl-C(O)— or (C1-C6)alkyl-SO2—;
- R14 is H, halogen, C1-C6 alkyl, hydroxy(C1-C6)alkyl, C1-C6 alkoxy(C1-C6)alkyl, thio(C1-C6)alkyl, (C1-C6)alkylthio(C1-C6)alkyl or NR2R3—(C1-C6)alkyl; and
- R15 is H, halogen, C1-C6 alkyl or C1-C6 alkoxy.
- Preferred compounds of formula V are those wherein R is R1-furanyl, R1-thienyl, R1-pyrrolyl, R1-pyridyl or R10-phenyl, more preferably R1-furanyl or R10-phenyl. R1 is preferably hydrogen or halogen. R10 is preferably hydrogen, halogen, alkyl or —CF3. Another group of preferred compounds is that wherein X is alkylene, preferably ethylene. Y is preferably
- wherein Q is
- with Q preferably being nitrogen. Preferably, m and n are each 2, and R4 is H. A preferred definition for Z is R5-phenyl or R5-heteroaryl. R5 is preferably H, halogen, alkyl, alkoxy, hydroxyalkoxy or alkoxyalkoxy. R6 is preferably R5-phenyl.
- Preferred specific compounds of formula V are those of the formula VA
- wherein R and Z-Y are as defined in the following table:
- WO 03/048165 discloses useful adenosine A2a receptor antagonist compounds having the structural formula VI
- or a pharmaceutically acceptable salt or solvate of said compound, wherein:
- R is selected from the group consisting of R1-furanyl-, R1-thienyl-, R1-pyridyl-, R1oxazolyl-, R1-pyrrolyl- and R2-aryl-;
- X is —(CH2)n—;
- Y is a piperidinyl, pyrrolidinyl or azepanyl group with an aryl or heteroaryl moiety fused to two adjacent carbon atoms on Y, wherein X is attached to the N atom of the piperidinyl, pyrrolidinyl or azepanyl group;
- Q is 1-4 substituents, which can be the same or different, and are independently selected from the group consisting of hydrogen, cycloalkyl, cycloheteroalkyl, amino, aryl, aralkyl, heteroaryl, alkyl, CF3, CN, halogen, NO2, alkoxy, alkoxyalkoxy, cycloalkylalkoxy, acyloxy, alkylamino, acylamino, alkylsulfonamino, alkylaminosulfonyl, dialkylaminosulfonyl, NH2SO2—, and hydroxy;
- n is 1 to 4;
- R1 is 1-3 substituents, which may be the same or different, and are independently selected from the group consisting of hydrogen, alkyl, CF3, halogen and NO2; and
- R2 is 1-3 substituents, which may be the same or different, and are independently selected from the group consisting of hydrogen, alkyl, CF3, halogen, NO2, alkoxy, acyloxy, alkylamino, acylamino, alkylsulfonamido, alkylaminosulfonyl, dialkylaminosulfonyl, aminosulfonyl, and hydroxyl.
- In a preferred embodiment of compounds of formula VI, Y is
- wherein A1 is N—X, and A2 and A3 each are CR4R5, or
-
- A1 and A3 each are CR4R5, and A2 is N—X, or
- A1 and A2 each are CR4R5, and A3 is N—X;
- A4 is CR4R5;
- Z1, Z2, Z3 and Z4, which can the same or different, are each independently selected from the group consisting of N and CR3, provided that 0-2 of Z1, Z2, Z3 or Z4 are N and the remainder are CR3;
- Z5 is NR5, O, S or CR4R5;
- Z6 is N or CR3;
- Z7 is N or CR3;
- m is an integer from 0 to 2;
- R3 is selected from the group consisting of hydrogen, cycloalkyl, amino, aryl, heteroaryl, C1-C6-alkyl, CF3, CN, halogen, NO2, C1-C6-alkoxy, C1-C6-acyloxy, C1-C6-alkylamino, C1-C6-acylamino, C1-C6-alkylsulfonamino, C1-C6-alkylaminosulfonyl, C1-C6-dialkylaminosulfonyl, NH2—SO2—, and hydroxy;
- R4 is selected from the group consisting of hydrogen, hydroxyalkyl, aryl, aralkyl, C1-C6-alkyl, C1-C6-alkoxy, CF3, CN, halogen, hydroxy, and NO2; and
- R5 is hydrogen or C1-C6 alkyl.
- Preferred specific examples of compounds of formula VI include compounds of the formula:
- WO 03/048164 discloses useful adenosine A2a receptor antagonist compounds having the structural formula VII
- or a pharmaceutically acceptable salt or solvate thereof; wherein:
- R is selected from the group consisting of R4-heteroaryl, R5-phenyl, (C4-C6)cycloalkenyl, —C(═CH2)CH3, —C≡C—CH3,
-
- R2 is selected from the group consisting of —W—X, —NR19(CH2)m—W—X, and —NR19CH(CH3)—W—X, or
- R2 is selected from the group consisting of alkyl, alkenyl and —NR18R19, wherein said alkyl, alkenyl or —NR18R19 is optionally substituted by —W—X;
- R3 is selected from the group consisting of H, halo, alkyl, trifluoromethyl, alkoxy, alkoxyalkyl, hydroxyalkyl, alkylamino, alkylaminoalkyl, dialkylamino, dialkylaminoalkyl, aminoalkyl, aryl, heteroaryl, and CN;
- R4 is 1 to 3 substituents, which can be the same or different, and are independently selected from the group consisting of hydrogen, (C1-C6)-alkyl, —CF3, halogen, —NO2, —NR15R16, (C1-C6)alkoxy, (C1-C6)alkylthio, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, —COOR17 and —C(O)NR6R7;
- R5 is 1 to 5 substituents, which can be the same or different, and are independently selected from the group consisting of hydrogen, halogen, (C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, —CN, —NH2, (C1-C6)alkylamino, di-((C1-C6)alkyl)amino, —CF3, —OCF3, —S(O)0-2(C1-C6)alkyl and —CH2—SO2-phenyl;
- R6 and R7, which can be the same or different, are each independently selected from the group consisting of hydrogen and (C1-C6)alkyl;
- R8 is 1 to 5 substituents, which can be the same or different, and are independently selected from the group consisting of hydrogen, halogen, (C1-C6)alkyl, hydroxy, C1-C6 alkoxy, —CN, amino, di-((C1-C6)alkyl)amino, —CF3, —OCF3, acetyl, —NO2, hydroxy(C1-C6)alkoxy, (C1-C6)-alkoxy(C1-C6)alkoxy, di-((C1-C6)-alkoxy)(C1-C6)alkoxy, (C1-C6)alkoxy(C1-C6)alkoxy-(C1-C6)-alkoxy, carboxy(C1-C6)-alkoxy, (C1-C6)alkoxycarbonyl(C1-C6)alkoxy, (C3-C6)cycloalkyl(C1-C6)alkoxy, di-((C1-C6)alkyl)amino(C1-C6)alkoxy, morpholinyl, (C1-C6)alkyl-SO2—, (C1-C6)alkyl-SO2—(C1-C6)alkoxy, tetrahydropyranyloxy, (C1-C6)alkylcarbonyl(C1-C6)-alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyloxy(C1-C6)-alkoxy, —SO2NH2, phenoxy,
- adjacent R8 substituents together are —O—CH2—O—, —O—CH2CH2—O—, —O—CF2—O—or
- —O—CF2CF2—O— and form a ring with the carbon atoms to which they are attached;
- R9 is selected from the group consisting of (C1-C6)alkyl, R8-aryl-, R8-aryl(C1-C6)alkyl-, thienyl, pyridyl, (C3-C6)-cycloalkyl, (C1-C6)alkyl-OC(O)—NH—(C1-C6)alkyl-, di-((C1-C6)alkyl)aminomethyl, cycloheteroalkyl(C1-C6)alkyl, aryloxy(C1-C6)alkyl, alkoxy(C1-C6)alkyl and
- R10 is 1-2 substituents, which can be the same or different, and are independently selected from the group consisting of hydrogen, (C1-C6)alkyl, R5-aryl and R4-heteroaryl, or two R10 substituents on the same carbon can form ═O;
- R11 is hydrogen or (C1-C6)alkyl; —C(O)alkyl, or R17 and R11 taken together are —(CH2)p-A-(CH2)q, wherein p and q are each independently 2 or 3 and A is selected from the group consisting of a bond, —CH2—, —S— and —O—, and form a ring with the nitrogen to which they are attached;
- R12 is 1-2 substituents, which can be the same or different, and are independently selected from the group consisting of hydrogen, (C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, halogen, and —CF3;
- R13 is selected from the group consisting of H, (C1-C6)alkyl, phenyl, benzyl, (C2-C6)alkenyl, (C1-C6)alkoxy(C1-C6)alkyl, di-((C1-C6)alkyl)amino(C1-C6)alkyl, pyrrolidinyl(C1-C6)alkyl and piperidino(C1-C6)alkyl;
- R14 is selected from the group consisting of H, halogen, (C1-C6)alkyl or (C1-C6)alkoxy;
- R15 is selected from the group consisting of H and (C1-C6)alkyl;
- R16 is selected from the group consisting of H, (C1-C6)alkyl-C(O)— and (C1-C6)alkyl-SO2—;
- R17 is selected from the group consisting of (C1-C6)alkyl, (C1-C6)hydroxyalkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy(C1-C6)alkoxy, (C1-C6)alkoxy, (C1-C6)alkoxy(C1-C6)alkyl, allyl, propargyl, R8-heteroaryl-, R8-aryl- and R8-aryl(C1-C6)alkyl-;
- R18 is selected from the group consisting of a bond, —CH2—, —CH(OH)—, —CH(CH3)—, —C(CH3)n—, —(CH2)n—, and —O(CH2)n—,
- R19 is selected from the group consisting of H, (C1-C6)alkyl, (C1-C6)alkyl(C1-C6)cycloalkyl, (C1-C6)cycloalkyl(C1-C6)alkyl and (C1-C6)alkoxy(C1-C6)alkyl;
- Q and Q1 can be the same or different and are each independently selected from the group consisting of
- m and n are each independently 1-3;
- p and q are each independently 0-2;
- s is 0-4;
- W is aryl or heteroaryl having 1-3 heteroatoms, which can be the same or different, and are independently selected from the group consisting of N, O and S, and wherein said aryl or heteroaryl is optionally substituted with 1-3 substituents, which can be the same or different, and are independently selected from the group consisting of alkyl, aryl, alkylcycloalkyl, halo, hydroxy, hydroxyalkyl, alkoxy, alkylalkoxy, alkoxyalkoxy, —NR6R7, (C2-C6)alkene, and —CN, or
- X is selected from the group consisting of H, NH2, —N(R6)(CH2)s-aryl, —N(R6)(CH2)s-heteroaryl, —N(R6)(CH2)m+1—OH, and —N(CH3)2, or
- X is —R18—Y-Z;
- Y is selected from the group consisting of —N(R6)CH2CH2N(R7)—, —N(R6)(CH2)naryl, —OCH2CH2N(R6)—, —O—, —S—, —CH2S—, —(CH2)2-3—N(R6)—, R8-divalent heteroaryl,
- and
- Z is selected from the group consisting of H, alkyl, alkoxyalkyl, R8-aryl-, R8-aryl(C1-C6)alkyl-, R8-heteroaryl-, R8-bicyclicalkyl-, aminoalkyl, alkylamino, NH2, —N—(R6)(CH2)s-aryl, —N(R6)(CH2)s-heteroaryl, —N(R6)C(O)OR17, alkylcycloheteroalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, alkoxycycloheteroalkyl, heteroaryl; R8-benzofused heteroaryl-, diphenylmethyl and R9—C(O)—; or
- when Y is
- Z can also be —OH, R9—SO2—, R17—N(R11)(CH2)s—C(O), R17—OC(O)—, R17—O(CH2)nC(O)—, benzofused heteroaryl(CH2)nC(O)—, benzofused heteroaryl(CH2)n— or R17—N(R11)—C(S)—;
or - when Q is
- Z can also be R17R11N—, phenylamino or pyridylamino; or
- Z and Y taken together are selected from the group consisting of
- Preferred compounds of formula VII are those having the following structures:
- WO 03/048163 discloses useful adenosine A2a receptor antagonist compounds having the structural formula VII
- or a pharmaceutically acceptable salt thereof, wherein:
- A is C(R1) or N;
- R1 and R1a are independently selected from the group consisting of H, (C1-C6)-alkyl, halo, CN and —CF3;
- Y is —O—, —S—, —SO—, —SO2—, R5-heteroaryldiyl, R5-arylene or
- p and q are independently 2-3;
- Q and Q1 are independently selected from the group consisting of
- provided that at least one of Q and Q1 is
- R is R5-aryl, R5-heteroaryl, R6—(C2-C6)alkenyl or R6—(C2-C6)alkynyl;
- R2 is R5-aryl, R5-heteroaryl, R5-aryl(C1-C6)alkyl or R5-heteroaryl(C1-C6)alkyl; or R2—Y is
- U, V, and W are independently selected from the group consisting of N and CR1, provided that at least one of U, V and W is CR1;
- n is 1, 2 or 3; and
-
- (a) A is C(R1) and X is —C(R3)(R3a)—, —C(O)—, —O—, —S—, —SO—, —SO2—, R4-arylene, R4-heteroarldiyl, or —N(R9)—; or A is C(R1), Y is a bond, and X is —C(R3)(R3a), —C(O)—, —O—, —S—, —SO—, —SO2—, R4-arylene, —N(R9)— or R4-heteroaryldiyl, provided that when X is —N(R9)— or R4-heteroaryldiyl, R2 is not phenyl or phenyl-(C1-C6)alkyl; or
- (b) A is N, X is —N(R9)—, Y is R5-arylene and R2 is
- or n is 2 or 3; and
-
- (c) A is N and X is —C(R3)(R3a)—, —C(O)—, —O—, —S—, —SO—, —SO2—, —N(R9)—, R4-arylene or R4-heteroaryldiyl; or A is N, Y is a bond and X is —C(O)—, —N(R9)—, R4-arylene or R4-heteroaryldiyl; or A is N, Y is —N(R9a), —C(O)N(R9a)— or —O—(CH2)2—N(R9a)—, and X is —N(R9)—; or A is N, X is —N(R9)—, and Y and R2 together are
- or n is 0; and
-
- (d) A is N, Y is a bond, X is —N(R9)—, and R2 is
-
- (e) A is N, X is —N(R9)— and Y and R2 together are
-
-
- wherein Z is —(O)—CH2—, —C(O)—CH(C1-C6 alkyl), —CH2—CH(C1-C6 alkyl)-, or —CH(C1-C6 alkyl)-CH2—;
-
- R3 and R3a are independently selected from the group consisting of H, —OH, C1-C6 alkyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl and di(C1-C6)alkylamino(C1-C6)alkyl;
- R4 is 1-3 substituents selected from the group consisting of H, (C1-C6)alkyl, —OH, (C1-C6)alkoxy, (C1-C6)alkoxy(C1-C6)alkoxy, halo, —CF3, and —CN;
- R5 is 1-3 substituents independently selected from the group consisting of H, (C1-C6)alkyl, —OH, (C1-C6)alkoxy, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkoxy, halo, —CF3, —CN, —NH2, (C1-C6)alkylamino, di(C1-C6)alkylamino, amino(C1-C6)-alkyl, (C1-C6)alkylamino(C1-C6)alkyl, di(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkanoyl-amino, (C1-C6)alkanesulfonylamino, (C1-C6)alkylthio, (C1-C6)alkylthio(C1-C6)alkyl,
- R6—(C2-C6)alkenyl, R6—(C2-C6)alkynyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy-C(O)-amino, or heterocycloalkyl(C1-C6)alkyl;
- R6 is 1 to 3 substituents independently selected from the group consisting of H, —OH, (C1-C6)alkoxy and halo;
- R7 and R7a are independently selected from the group consisting of H, (C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, R8-aryl and R8-heteroaryl, or an R7 and an R7a substituent on the same carbon can form ═O;
- R8 is 1 to 3 substituents independently selected from H, (C1-C6)alkyl, —OH, (C1-C6)alkoxy, (C1-C6)alkoxy(C1-C6)alkoxy, halo, —CF3, and —CN;
- R9 and R9a are independently selected from the group consisting of H, (C1-C6)alkyl, hydroxy(C2-C6)alkyl, (C1-C6)alkoxy(C2-C6)alkyl, amino(C2-C6)alkyl, (C1-C6)alkylamino(C2-C6)alkyl, di(C1-C6)alkylamino(C2-C6)alkyl, halo-(C3-C6)alkenyl, CF3—(C1-C6)alkyl, (C3-C6)alkenyl, (C3-C6)cycloalkyl and (C3-C6)cycloalkyl-(C1-C6)alkyl; and
- R10 is H, —C(O)—O—(C1-C6)alkyl, R5-aryl, —C(O)—(C1-C6)alkyl, —C(O)—(R5-aryl) or R5-aryl-(C1-C6)alkyl.
- Preferred compounds of formula VIII are those wherein A is N. R is preferably furyl. R1a is preferably hydrogen. Another group of preferred compounds is that wherein X is —O—, —S—, —N(R9)— or R4-arylene, with compounds wherein X is —N(R9)— being more preferred. R9 is preferably C1-C6 alkyl. Preferred definitions for Y are a bond or piperazinyl. R2 is preferably R5-aryl. When Y and/or R2 is
- Q is preferably N, Q1 is preferably N, p and q are each preferably 2, each R7 and R7a is preferably hydrogen, and R10 is preferably —C(O)—O—(C1-C6)alkyl, —C(O)—(C1-C6)alkyl or —C(O)—(R5-aryl). R5 is preferably 1 or 2 substituents selected from the group consisting of H, (C1-C6)alkoxy, (C1-C6)alkoxy(C1-C6)-alkoxy, halo and —CF3. R4 is preferably H, halo or (C1-C6)alkyl. R3 and R3a are preferably independently selected from H and (C1-C6)alkyl. R9a is preferably H or (C1-C6)alkyl. R6 is preferably hydrogen.
- Preferred specific examples of compounds of formula VIII include compounds of the formula
- wherein R2—Y—(CH2)n—N(R9)— is as defined in the table:
- WO 01/02409 discloses useful adenosine A2a receptor antagonist compounds having the structural formula IX
- wherein
- X is O or S;
- R1 and R2 are independently selected from hydrogen, alkyl, aryl, hydroxy, alkoky, aryloxy, cyano, nitro, CO2R7, COR7, OCOR7, CONR7R8, CONR7NR8R9, OCONR7R8, NR7R8, NR7COR8, NR7CONR8R9, NR7CO2R8, NR7SO2R8, NR7CONR8NR9R10, NR7NR8CO2R9, NR7NR8CONR9R10, NR7SO2NR8R9, SO2R7, SOR7, SR7 and SO2NR7R8, or R1 and R2 together form a carbonyl group (C═O), an oxime group (C═NOR11), an imine group (C═NR1) or a hydrazine group (C═NNR11R12), or R1 and R2 together form a 5, 6 or 7 membered carbocyclic or heterocyclic ring;
- R3 is alkyl or aryl;
- R4, R5 and R6 ate independently selected from hydrogen, alkyl, aryl, halogen, hydroxy, nitro, cyano, alkoxy, aryloxy, CO2R7, COR7, OCOR7, SO2R7, SOR7, SR7, SO2NR7R8, CONR7R8, CONR7NR8R9, OCONR7R8, NR7R8, NR7COR8, NR7CONR8R9, NR7CO2R8, NR7SO2R8, CR7═NOR8, NR7CONR8NR9R10, NR7NR8CO2R9, NR7NR8CONR9R10, SO2NR7NR8R9, NR7SO2NR8R9, NR7NR8SO2R9, NR7NR8CO2R9, NR7NR8R9 and NR7CSNR8R9, or R5 and R6 together form a 5, 6 or 7 membered carbocyclic or heterocyclic ring; and
- R7, R8, R9, R10, R11 and R12 are independently selected from hydrogen, alkyl and aryl, or a pharmaceutically acceptable salt or prodrug thereof.
- The US patents and applications cited herein are incorporated herein by reference. The adenosine A2a receptor antagonists are prepared by known methods as described in the cited patents and applications.
- As used herein, “patient” means a mammal, especially a human.
- It is contemplated that more than one adenosine A2a receptor antagonist (e.g., 2 or 3) can be administered to treat EPS, dystonia, RLS or PLMS; preferably, one adenosine A2a receptor antagonist is administered.
- Antipsychotic agents causing the EPS treated by adenosine A2a receptor antagonists and for use in combination with adenosine A2a receptor antagonists include typical and atypical antipsychotic agents. Typical antipsychotics include loxapine, haloperidol, chlorpromazine, prochlorperazine and thiothixene. Atypical antipsychotics include clozapine, olanzapine, loxapine, quetiapine, ziprasidone and risperidone.
- Tricyclic antidepressants causing dystonia treated by adenosine A2a receptor antagonists include perphenazine, amitriptyline, desipramine, doxepin, trimipramine and protriptyline. Anticonvulsants which may cause dystonia, but which also may be useful in treating ERLS or PLMS include phenyloin, carbamazepine and gabapentin.
- Dopamine agonists useful in treating RLS and PLMS include pergolide, pramipexole, ropinerole, fenoldopam and cabergoline.
- Opioids useful in treating PRLS and PLMS include codeine, hydrocodone, oxycodone, propoxyphene and tramadol.
- Benzodiazepines useful in treating PRLS and PLMS include clonazepam, triazolam and temazepam.
- The antipsychotics, tricyclic antidepressants, anticonvulsants, dopamine agonists, opioids and benzodiazepines are commercially available and are described in the literature, e.g., in The Physicians' Desk Reference (Montvale: Medical Economics Co., Inc., 2001).
- It is contemplated that two or more A2a receptor antagonists could be administered in combination with one or more other agents (e.g., antipsychotics, tricyclic antidepressants, anticonvulsants, dopamine agonists, opioids or benzodiazepines), although administration of one A2a antagonist in combination with one other agent is preferred for each of the indications. While administration of separate dosage forms of the A2a antagonist(s) and the other agent(s) are preferred, it is also contemplated that the other agent(s) could be combined in a single dosage form with the A2a receptor antagonist(s) for the treatment or prevention of EPS, dystonia, RLS or PLMS.
- Preferred adenosine A2a antagonists are those described in U.S. Pat. No. 6,630,475.
- A particularly preferred compound of the invention is Compound A of the formula
- or a pharmaceutically acceptable salt or solvate thereof, disclosed in U.S. Pat. No. 6,630,475 and listed as the first compound in the table of compounds of structure I.
- Compounds useful in the method of the invention will show utility as adenosine A2a receptor antagonists in these assays.
- Membrane sources: A2a: Human A2a Adenosine Receptor membranes, Catalog #RB-HA2a, Receptor Biology, Inc., Beltsville, Md. Dilute to 17 μg/100 μl in membrane dilution buffer (see below).
Assay Buffers Membrane dilution buffer: Dulbecco's Phosphate Buffered Saline (Gibco/BRL)+10 mM MgCl2.
Compound Dilution Buffer: Dulbecco's Phosphate Buffered Saline (Gibco/BRL)+10 mM MgCl2 supplemented with 1.6 mg/ml methyl cellulose and 16% DMSO. Prepared fresh daily.
Ligands: A2a: [3H]-SCH 58261, custom synthesis, AmershamPharmacia Biotech, Piscataway, N.J. Stock is prepared at 1 nM in membrane dilution buffer. Final assay concentration is 0.5 nM. - A1: [3H]-DPCPX, AmershamPharmacia Biotech, Piscataway, N.J. Stock is prepared at 2 nM in membrane dilution buffer. Final assay concentration is 1 nM.
- A2a: To determine non-specific binding, add 100 nM CGS 15923 (RBI, Natick, Mass.). Working stock is prepared at 400 nM in compound dilution buffer.
- A1: To determine non-specific binding, add 100 μM NECA (RBI, Natick, Mass.). Working stock is prepared at 400 μM in compound dilution buffer.
- Prepare 1 mM stock solutions of compounds in 100% DMSO. Dilute in compound dilution buffer. Test at 10 concentrations ranging from 3 μM to 30 μM. Prepare working solutions at 4× final concentration in compound dilution buffer.
- Perform assays in deep well 96 well plates. Total assay volume is 200 μl. Add 50 μl compound dilution buffer (total ligand binding) or 50 μl CGS 15923 working solution (A2a non-specific binding) or 50 μl NECA working solution (A1 non-specific binding) or 50 μl of drug working solution. Add 50 μl ligand stock ([3H]-SCH 58261 for A2a, [3H]-DPCPX for A1). Add 100 μl of diluted membranes containing the appropriate receptor. Mix. Incubate at room temperature for 90 minutes. Harvest using a Brandel cell harvester onto Packard GF/B filter plates. Add 45 μl Microscint 20 (Packard), and count using the Packard TopCount Microscintillation Counter. Determine IC50 values by fitting the displacement curves using an iterative curve fitting program (Excel). Determine Ki values using the Cheng-Prusoff equation.
- Male Sprague-Dawley rats (Charles River, Calco, Italy) weighing 175-200 g are used. The cataleptic state is induced by the subcutaneous administration of the dopamine receptor antagonist haloperidol (1 mg/kg, sc), 90 min before testing the animals on the vertical grid test. For this test, the rats are placed on the wire mesh cover of a 25×43 plexiglas cage placed at an angle of about 70 degrees with the bench table. The rat is placed on the grid with all four legs abducted and extended (“frog posture”). The use of such an unnatural posture is essential for the specificity of this test for catalepsy. The time span from placement of the paws until the first complete removal of one paw (descent latency) is measured maximally for 120 sec.
- The selective A2a adenosine antagonists under evaluation are administered orally at doses ranging between 0.03 and 3 mg/kg, 1 and 4 h before scoring the animals.
- In separate experiments, the anti-cataleptic effects were determined for the reference compound, L-DOPA (25, 50 and 100 mg/kg, ip),
- For preparing pharmaceutical compositions from the compounds useful in the method of this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 0.1 to about 99 percent active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar, lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.
- For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
- Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection.
- Liquid form preparations may also include solutions for intranasal administration.
- Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas.
- Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
- The compounds useful in the method of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
- Preferably the adenosine A2a receptor antagonist and the antipsychotic are administered orally.
- Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
- The quantity of adenosine A2a receptor antagonist in a unit dose of preparation may be varied or adjusted from about 0.1 mg to 1000 mg, more preferably from about 1 mg to 300 mg, according to the particular application.
- The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
- The amount and frequency of administration of the adenosine A2a receptor antagonist useful in the method of the invention will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended dosage regimen for an adenosine A2a receptor antagonist is oral administration of about 10 mg to 2000 mg/day preferably 10 to 1000 mg/day, in two to four divided doses to provide relief from the effects of EPS, dystonia, RLS or PLMS. The compounds are non-toxic when administered within this dosage range.
- The doses and dosage regimen of the other agents used in combination with the adenosine A2a receptor antagonists, i.e., the antipsychotics, tricyclcic antidepressants, anticonvulsants, dopamine agonists, benzodiazepines, opioids, lithium or iron, will be determined by the attending clinician in view of the approved doses and dosage regimen in the package insert, taking into consideration the age, sex and condition of the patient and the severity of the disease. When administered in combination, the adenosine A2a receptor antagonist and the other agent can be administered simultaneously or sequentially. This is particularly useful when the components of the combination are preferably given on different dosing schedules, e.g., one component is administered daily and the other every six hours, or when the preferred pharmaceutical compositions are different, e.g. one is preferably a tablet and one is a capsule. It is therefore advantageous to provide the adenosine A2a receptor antagonist and the other agent in a kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat or prevent EPS, dystonia, RLS or PLMS, wherein one container comprises a pharmaceutical composition comprising an effective amount of an adenosine A2a receptor antagonist in a pharmaceutically acceptable carrier, and wherein a separate container comprises a pharmaceutical composition comprising an effective amount of another agent appropriate to treat the indicated condition.
- Those skilled in the art will recognize that a dosage form for one of the components of the combination can be modified to contain both an adenosine A2a receptor antagonist and another agent, e.g., an adenosine A2a receptor antagonist and an antipsychotic or an adenosine A2a receptor antagonist and a dopamine agonist.
- The following example shows the use of adenosine A2a antagonists to attenuate the Extra-Pyramidal Syndrome (EPS) displayed in cebus apella monkeys sensitized to the dopamine D2 receptor antagonist, haloperidol.
- A colony of seven Cebus apella monkeys that were previously sensitized to the chronic effects of haloperidol, exhibit EPS when administered haloperidol acutely (0.3 mg/kg, p.o.). Compound A was administered orally (p.o.) at doses of 0.3-30 mg/kg, in conjunction with haloperidol. The studies were conducted using a within-subjects design such that each monkey received all 6 treatments (vehicle and 5 doses of Compound A) in a crossover, balanced design. In all the studies, the group of seven monkeys exhibited baseline levels of EPS when dosed with haloperidol.
- Compound A produced a dose-dependent reduction in the maximum EPS score (
FIG. 1A ), as well as a dose-dependent delay in the onset of EPS (FIG. 1B ). At a dose of 1 mg/kg, Compound A prevented the onset of EPS in one monkey, and delayed the onset of EPS by 1 hr. Compound A, at a dose of 3 mg/kg, prevented the onset of EPS in two monkeys, and delayed the onset of EPS by almost 2 hr in the remaining monkeys. At 10 and 30 mg/kg, Compound A prevented the onset of EPS in three monkeys and delayed the onset of EPS by an average of 2.3-2.9 hr. - Clinical guidelines for the treatment of RLS and PLMS have been established: see A. L. Chesson et al, Sleep, 22, 7 (1999), p. 961-8. Efficacy of adenosine A2a antagonists in treating RLS and PLMS can be determined by a method analogous to the clinical method described in the literature for pramipexole and ropinerole by Weimerskirch et al, Annals of Pharmacotherapy, 35, 5 (2001), p. 627-30.
- While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.
Claims (19)
1. A method for the treatment or prevention of Extra-Pyramidal Syndrome or dystonia comprising administering a therapeutically effective amount of an adenosine A2a receptor antagonist to a patient in need thereof.
2. The method of claim 1 wherein the adenosine A2a antagonist is a compound of the formula
or a pharmaceutically acceptable salt thereof, wherein
R is R1-furanyl, R1-thienyl, R1-pyridyl, R1-pyridyl N-oxide, R1-oxazolyl, R10-phenyl, R1-pyrrolyl or C4-C6 cycloalkenyl;
X is C2-C6 alkylene or —C(O)CH2—;
Y is —N(R2)CH2CH2N(R3)—, —OCH2CH2N(R2)—, —C—, —S—, —CH2S—, —(CH2)2—NH—, or
and
Z is R5-phenyl, R5-phenyl(C1-C6)alkyl, R5-heteroaryl, diphenylmethyl, R6—C(O)—, R6—SO2—, R6—OC(O)—, R7—N(R8)—C(O)—, R7—N(R8)—C(S)—,
phenyl-CH(OH)—, or phenyl-C(═NOR2)—; or when Q is
Z is also phenylamino or pyridylamino;
or
Z and Y together are
R1 is 1 to 3 substituents independently selected from hydrogen, C1-C6-alkyl, —CF3, halogen, —NO2, —NR12R13, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylsulfinyl, and C1-C6 alkylsulfonyl;
R2 and R3 are independently selected from the group consisting of hydrogen and C1-C6 alkyl;
m and n are independently 2-3;
Q is
R4 is 1-2 substituents independently selected from the group consisting of hydrogen and C1-C6alkyl, or two R4 substituents on the same carbon can form ═O;
R5 is 1 to 5 substituents independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, —CN, di-((C1-C6)alkyl)amino, —CF3, —OCF3, acetyl, —NO2, hydroxy(C1-C6)alkoxy, (C1-C6)-alkoxy(C1-C6)alkoxy, di-((C1-C6)-alkoxy)(C1-C6)alkoxy, (C1-C6)-alkoxy(C1-C6)alkoxy-(C1-C6)-alkoxy, carboxy(C1-C6)alkoxy, (C1-C6)-alkoxycarbonyl(C1-C6)alkoxy, (C3-C6)cycloalkyl(C1-C6)alkoxy, di-((C1-C6)alkyl)amino(C1-C6)alkoxy, morpholinyl, (C1-C6)alkyl-SO2—, (C1-C6)alkyl-SO—(C1-C6)alkoxy, tetrahydropyranyloxy, (C1-C6)alkylcarbonyl(C1-C6)alkoxy, (C1-C6)-alkoxycarbonyl, (C1-C6)alkylcarbonyloxy(C1-C6)-alkoxy, —SO2NH2, phenoxy,
or adjacent R5 substituents together are —O—CH2—O—, —O—CH2CH2—O—, —O—CF2—O— or —O—CF2CF2—O— and form a ring with the carbon atoms to which they are attached;
R6 is (C1-C6)alkyl, R5-phenyl, R5-phenyl(C1-C6)alkyl, thienyl, pyridyl, (C3-C6)cycloalkyl, (C1-C6)alkyl-OC(O)—NH—(C1-C6)alkyl-, di-((C1-C8)alkyl)aminomethyl, or
R7 is (C1-C6)alkyl, R5-phenyl or R5-phenyl(C1-C6)alkyl;
R8 is hydrogen or C1-C6 alkyl; or R7 and R6 together are —(CH2)p-A-(CH2)q, wherein p and q are independently 2 or 3 and A is a bond, —CH2—, —S— or —O—, and form a ring with the nitrogen to which they are attached;
R9 is 1-2 groups independently selected from hydrogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halogen, —CF3 and (C1-C6)alkoxy(C1-C6)alkoxy;
R10 is 1 to 5 substituents independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, —CN, —NH2, C1-C6alkylamino, di-((C1-C6)alkyl)amino, —CF3, —OCF3 and —S(O)0-2(C1-C6)alkyl;
R11 is H, C1-C6 alkyl, phenyl, benzyl, C2-C6 alkenyl, C1-C6 alkoxy(C1-C6)alkyl, di-((C1-C6)alkyl)amino(C 1-C6)alkyl, pyrrolidinyl(C1-C6)alkyl or piperidino(C1-C6)alkyl;
R12 is H or C1-C6 alkyl; and
R13 is (C1-C6)alkyl-C(O)— or (C1-C6)alkyl-SO2—.
5. The method of claim 1 for treating or preventing Extra-Pyramidal Syndrome.
6. The method of claim 5 wherein the Extra-Pyramidal Syndrome has been caused by treatment with a typical antipsychotic agent or an atypical antipsychotic agent.
7. The method of claim 6 wherein the typical antipsychotic agent is selected from the group consisting of loxapine, haloperidol, chlorpromazine, prochlorperazine and thiothixene, and the atypical antipsychotic agent is selected from the group consisting of clozapine, olanzapine, loxapine, quetiapine, ziprasidone and risperidone
8. The method of claim 5 further comprising administering an antipsychotic agent in combination with the adenosine A2a receptor antagonist.
9. The method of claim 8 wherein the antipsychotic agent is a typical antipsychotic agent selected from the group consisting of loxapine, haloperidol, chlorpromazine, prochlorperazine and thiothixene, or an atypical antipsychotic agent selected from the group consisting of clozapine, olanzapine, loxapine, quetiapine, ziprasidone and risperidone.
10. A kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat or prevent EPS caused by treatment with antipsychotic agent, wherein one container comprises a pharmaceutical composition comprising an effective amount of an adenosine A2areceptor antagonist in a pharmaceutically acceptable carrier, and wherein, a separate container comprises a pharmaceutical composition comprising an effective amount of an antipsychotic agent.
11. A method of claim 1 for the treatment of idiopathic dystonia or dystonia caused by the use of cocaine.
12. The method of claim 1 for the treatment or prevention of dystonia caused by treatment with a tricyclic antidepressant, lithium or an anticonvulsant.
13. The method of claim 12 further comprising administering a tricyclic antidepressant, lithium or an anticonvulsant in combination with the adenosine A2a receptor antagonist.
14. The method of claim 13 wherein the tricyclic antidepressant is selected from the group consisting of perphenazine, amitriptyline, desipramine, doxepin, trimipramine and protriptyline, and the anticonvulsant is selected from the group consisting of phenyloin, carbamazepine and gabapentin.
15. A kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat or prevent dystonia caused by treatment with a tricyclic antidepressant, lithium or an anticonvulsant, wherein one container comprises a pharmaceutical composition comprising an effective amount of an adenosine A2a receptor antagonist in a pharmaceutically acceptable carrier, and wherein, a separate container comprises a pharmaceutical composition comprising an effective amount of a tricyclic antidepressant, lithium or an anticonvulsant.
16. A method of treating restless leg syndrome or periodic leg movement in sleep comprising administering a therapeutically effective amount of an adenosine A2a receptor antagonist to a patient in need thereof.
17. The method of claim 16 wherein the adenosine A2a antagonist is a compound of the formula
or a pharmaceutically acceptable salt thereof, wherein
R is R1-furanyl, R1-thienyl, R1-pyridyl, R1-pyridyl N-oxide, R1-oxazolyl, R10-phenyl, R1-pyrrolyl or C4-C6 cycloalkenyl;
X is C2-C6 alkylene or —C(O)CH2—;
Y is —N(R2)CH2CH2N(R3)—, —OCH2CH2N(R2)—, —O—, —S—, —CH2S—, —(CH2)2—NH—, or
and
Z is R5-phenyl, R5-phenyl(C1-C6)alkyl, R5-heteroaryl, diphenylmethyl, R6—C(O)—, R6—SO2—, R6—OC(O)—, R7—N(R8)—C(O)—, R7—N(R8)—C(S)—,
phenyl-CH(OH), or phenyl-C(═NOR2)—; or when Q is
Z is also phenylamino or pyridylamino;
or
Z and Y together are
R1 is 1 to 3 substituents independently selected from hydrogen, C1-C6-alkyl, —CF3, halogen, —NO2, —NR12R13, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylsulfinyl, and C1-C6 alkylsulfonyl;
R2 and R3 are independently selected from the group consisting of hydrogen and C1-C6 alkyl;
m and n are independently 2-3;
Q is
R4 is 1-2 substituents independently selected from the group consisting of hydrogen and C1-C6alkyl, or two R4 substituents on the same carbon can form ═O;
R5 is 1 to 5 substituents independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, —CN, di-((C1-C6)alkyl)amino, —CF3, —OCF3, acetyl, —NO2, hydroxy(C1-C6)alkoxy, (C1-C6)-alkoxy(C1-C6)alkoxy, di-((C1-C6)-alkoxy)(C1-C6)alkoxy, (C1-C6)alkoxy(C1-C6)alkoxy-(C1-C6)-alkoxy, carboxy(C1-C6) alkoxy, (C1-C6)-alkoxycarbonyl(C1-C6)alkoxy, (C3-C6)cycloalkyl(C1-C6)alkoxy, di-((C1-C6)alkyl)amino(C1-C6)alkoxy, morpholinyl, (C1-C6)alkyl-SO2—, (C1-C6)alkyl-SO—(C1-C6)alkoxy, tetrahydropyranyloxy, (C1-C6)alkylcarbonyl(C1-C6)alkoxy, (C1-C6)-alkoxycarbonyl, (C1-C6)alkylcarbonyloxy(C1-C6)-alkoxy, —SO2NH2, phenoxy,
or adjacent R5 substituents together are —O—CH2—O—, —O—CH2CH2—O—, —O—CF2—O— or —O—CF2CF2—O— and form a ring with the carbon atoms to which they are attached;
R6 is (C1-C6)alkyl, R5-phenyl, R5-phenyl(C1-C6)alkyl, thienyl, pyridyl, (C3-C6)-cycloalkyl, (C1-C6)alkyl-OC(O)—NH—(C1-C6)alkyl-, di-((C1-C6)alkyl)aminomethyl, or
R7 is (C1-C6)alkyl, R5-phenyl or R5-phenyl(C1-C6)alkyl;
R8 is hydrogen or C1-C6 alkyl; or R7 and R8 together are —(CH2)p-A-(CH2)q, wherein p and q are independently 2 or 3 and A is a bond, —CH2—, —S— or —O—, and form a ring with the nitrogen to which they are attached;
R9 is 1-2 groups independently selected from hydrogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halogen, —CF3 and (C1-C6)alkoxy(C1-C6)alkoxy;
R10 is 1 to 5 substituents independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, —CN, —NH2, C1-C6alkylamino, di-((C1-C6)alkyl)amino, —CF3, —OCF3 and —S(O)0-2(C1-C6)alkyl;
R11 is H, C1-C6 alkyl, phenyl, benzyl, C2-C6 alkenyl, C1-C6 alkoxy(C1-C6)alkyl, di-((C1-C6)alkyl)amino(C1-C6)alkyl, pyrrolidinyl(C1-C6)alkyl or piperidino(C1-C6)alkyl;
R12 is H or C1-C6 alkyl; and
R13 is (C1-C6)alkyl-C(O)— or (C1-C6)alkyl-SO2—.
18. The method of claim 16 further comprising administering levodopa/carbidopa, levodopa/benserazide, a dopamine agonist, a benzodiazepine, an opioid, an anticonvulsant or iron in combination with the adenosine A2a receptor antagonist.
19. A kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat or prevent restless leg syndrome or periodic leg movement in sleep, wherein one container comprises a pharmaceutical composition comprising an effective amount of an adenosine A2a receptor antagonist in a pharmaceutically acceptable carrier, and wherein a separate container comprises a pharmaceutical composition comprising an effective amount of a dopamine agonist, benzodiazepine, opioid, anticonvulsant or iron.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/181,736 US20090029967A1 (en) | 2002-12-19 | 2008-07-29 | Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43532102P | 2002-12-19 | 2002-12-19 | |
US10/738,906 US7414058B2 (en) | 2002-12-19 | 2003-12-17 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
US12/181,736 US20090029967A1 (en) | 2002-12-19 | 2008-07-29 | Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/738,906 Continuation US7414058B2 (en) | 2002-12-19 | 2003-12-17 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090029967A1 true US20090029967A1 (en) | 2009-01-29 |
Family
ID=34572685
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/738,906 Expired - Fee Related US7414058B2 (en) | 2002-12-19 | 2003-12-17 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
US12/181,736 Abandoned US20090029967A1 (en) | 2002-12-19 | 2008-07-29 | Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/738,906 Expired - Fee Related US7414058B2 (en) | 2002-12-19 | 2003-12-17 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
Country Status (16)
Country | Link |
---|---|
US (2) | US7414058B2 (en) |
EP (3) | EP1578409B1 (en) |
JP (3) | JP2006514697A (en) |
CN (2) | CN100415217C (en) |
AT (1) | ATE490775T1 (en) |
AU (2) | AU2003304527B2 (en) |
BR (1) | BR0317436A (en) |
DE (1) | DE60335294D1 (en) |
ES (1) | ES2354875T3 (en) |
HK (1) | HK1074585A1 (en) |
MX (1) | MXPA05006790A (en) |
NO (1) | NO20053509L (en) |
NZ (1) | NZ540493A (en) |
TW (1) | TWI331036B (en) |
WO (1) | WO2005044245A1 (en) |
ZA (1) | ZA200504478B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060128694A1 (en) * | 2002-12-19 | 2006-06-15 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
US20070053993A1 (en) * | 2005-02-04 | 2007-03-08 | Sitkovsky Michail V | Method to predict and prevent oxygen-induced inflammatory tissue injury |
WO2014105664A1 (en) * | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Piperazine-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2014105666A1 (en) * | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2018013951A1 (en) * | 2016-07-15 | 2018-01-18 | Northwestern University | Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY132006A (en) * | 2000-05-26 | 2007-09-28 | Schering Corp | ADENOSINE A2a RECEPTOR ANTAGONISTS |
DE10043321B4 (en) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Use of a transdermal therapeutic system for the treatment of Parkinson's disease, for the treatment and prevention of premenstrual syndrome and for lactation inhibition |
DE10053397A1 (en) * | 2000-10-20 | 2002-05-02 | Schering Ag | Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases |
DE10064453A1 (en) * | 2000-12-16 | 2002-07-04 | Schering Ag | Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases |
CN100415217C (en) * | 2002-12-19 | 2008-09-03 | 先灵公司 | Uses of adenosine A2A receptor antagonists |
US20060106040A1 (en) * | 2002-12-19 | 2006-05-18 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
PE20050141A1 (en) * | 2003-04-23 | 2005-04-01 | Schering Corp | DERIVATIVES OF 2-ALKINYL-AND 2-ALKENYL-PIRAZOLO- [4,3-e] -1,2,4-TRIAZOLO- [1,5-c] -PYRIDINE AS ANTAGONISTS OF THE A2a ADENOSINE RECEPTOR |
NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
DE602005020127D1 (en) | 2004-04-21 | 2010-05-06 | Schering Corp | PYRAZOLOÄ4,3-EÜ-1,2,4-TRIAZOLOÄ1,5-CÜPYRIMIDINE AS ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR |
CA2581105A1 (en) | 2004-09-22 | 2006-03-30 | H. Lundbeck A/S | 2-acylaminothiazole derivatives |
US7674912B2 (en) * | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
JPWO2006132275A1 (en) * | 2005-06-07 | 2009-01-08 | 協和醗酵工業株式会社 | Preventive and / or therapeutic agent for movement disorders |
EP1934227B1 (en) | 2005-09-19 | 2011-12-21 | Schering Corporation | 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
PE20070521A1 (en) | 2005-09-23 | 2007-07-13 | Schering Corp | 7- [2- [4- (6-FLUORO-3-METHYL-1,2-BENZYSOXAZOL-5-IL) -1-PIPERAZINYL] ETHYL] -2- (1-PROPINYL) -7H-PIRAZOLE- [4, 3-E] - [1,2,4] -TRIAZOL- [1,5-C] -PYRIMIDIN-5-AMINE AS ANTAGONIST OF THE ADENOSINE A2a RECEPTOR |
ES2273599B1 (en) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | COMPOUNDS FOR THE TREATMENT OF HEADPHONE FIBRILATION. |
WO2009111449A1 (en) | 2008-03-04 | 2009-09-11 | Schering Corporation | 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists |
TWI473614B (en) * | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
BRPI1009398A2 (en) | 2009-03-13 | 2016-03-08 | Advinus Therapeutics Private Ltd | substituted fused pyrimidine compounds |
WO2011055391A1 (en) | 2009-11-09 | 2011-05-12 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
US8435994B2 (en) | 2009-11-16 | 2013-05-07 | Merck Sharp & Dohme Corp. | Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists |
US8473582B2 (en) * | 2009-12-16 | 2013-06-25 | International Business Machines Corporation | Disconnected file operations in a scalable multi-node file system cache for a remote cluster file system |
WO2011101861A1 (en) | 2010-01-29 | 2011-08-25 | Msn Laboratories Limited | Process for preparation of dpp-iv inhibitors |
KR101993867B1 (en) | 2010-02-05 | 2019-06-27 | 헵테얼즈 테라퓨틱스 리미티드 | 1,2,4-triazine-4-amine derivatives |
JP5843869B2 (en) * | 2010-09-24 | 2016-01-13 | アドヴィナス・セラピューティックス・リミテッド | Condensed tricyclic compounds as adenosine receptor antagonists |
WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
WO2012135084A1 (en) * | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
CN105025899B (en) * | 2012-12-28 | 2017-08-18 | 默沙东公司 | With A2AThe miscellaneous two cyclosubstituted amines of [1,2,4] triazol [1,5 c] quinazoline 5 of antagonist properties |
AU2018294557A1 (en) * | 2017-06-30 | 2020-01-02 | Ryvu Therapeutics S.A. | Imidazo(1,2-a)pyrazine modulators of the adenosine A2A receptor |
CA3086282A1 (en) | 2017-12-19 | 2019-06-27 | Impetis Biosciences Ltd. | Pharmaceutical composition for the treatment of cancer |
IL275817B2 (en) | 2018-01-04 | 2024-04-01 | Impetis Biosciences Ltd | Tricyclic compounds, compositions and medicinal applications thereof |
DE102019116986A1 (en) | 2019-06-24 | 2020-12-24 | Helmholtz-Zentrum Dresden-Rossendorf E. V. | Deuterated 7- (3- (4- (2 - ([18F] fluoro) ethoxy) phenyl) propyl) -2- (furan-2-yl) -7H-pyrazolo [4,3-e] [1,2, 4] triazolo [1,5-c] pyrimidin-5-amine derivatives |
US20230024108A1 (en) * | 2019-07-17 | 2023-01-26 | Teon Therapeutics, Inc. | Adenosine a2a receptor antagonists |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5565460A (en) * | 1993-07-27 | 1996-10-15 | Kyowa Hakko Koygo Co., Ltd. | Therapeutic purine agents for parkinson's disease |
US5933964A (en) * | 1996-07-17 | 1999-08-10 | Wahl Clipper Corporation | Cutter blade for hair clippers |
US20030139395A1 (en) * | 2001-09-13 | 2003-07-24 | Schering Corporation | Combination of an adenosine A2a receptor antagonist and an antidepressant or anxiolytic |
US6630475B2 (en) * | 2000-05-26 | 2003-10-07 | Schering Corporation | Adenosine A2a receptor antagonists |
US7414058B2 (en) * | 2002-12-19 | 2008-08-19 | Schering Corporation | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1264901B1 (en) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | HETEROCYCLIC ANALOGUES OF 1,2,4-TRIAZOLE(15-C)PYRIMIDINES WITH ANTAGONIST ACTIVITY FOR THE ADENOSINE A2 RECEPTOR |
IT1277392B1 (en) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | HEROCYCLIC ANALOGS OF 1,2,4-TRIAZOLE (1,5-C] PYRIMIDINE WITH ANTAGONIST ACTIVITY FOR THE A2A RECEPTOR OF ADENOSINE |
WO1999026627A1 (en) | 1997-11-26 | 1999-06-03 | Cerebrus Limited | (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders |
GB9819384D0 (en) * | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
GB9915437D0 (en) * | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
EP1379269B1 (en) * | 2001-04-09 | 2009-03-04 | Neurosearch A/S | Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease |
PE20030477A1 (en) | 2001-10-15 | 2003-06-06 | Schering Corp | ADENOSINE A2a RECEPTOR ANTAGONISTS |
EP1448565B1 (en) | 2001-11-30 | 2009-12-30 | Schering Corporation | ADENOSINE A2a RECEPTOR ANTAGONISTS |
PE20030739A1 (en) | 2001-11-30 | 2003-08-28 | Schering Corp | ADENOSINE A2A RECEPTOR ANTAGONISTS |
ES2283625T3 (en) * | 2001-11-30 | 2007-11-01 | Schering Corporation | ADENOSINE RECEPTOPR A2A ANTAGONISTS OF (1,2,4) -BYCLIC TRIAZOL. |
PT2260850T (en) | 2002-01-28 | 2018-10-24 | Kyowa Hakko Kogyo Kk | A2a receptor antagonists for use in the treatment of movement disorders |
ES2310258T5 (en) * | 2002-08-30 | 2012-05-31 | Kyowa Hakko Kogyo Co., Ltd. | Adenosine A2A receptor antagonists to treat restless legs syndrome or nocturnal myoclonus |
PE20050141A1 (en) | 2003-04-23 | 2005-04-01 | Schering Corp | DERIVATIVES OF 2-ALKINYL-AND 2-ALKENYL-PIRAZOLO- [4,3-e] -1,2,4-TRIAZOLO- [1,5-c] -PYRIDINE AS ANTAGONISTS OF THE A2a ADENOSINE RECEPTOR |
-
2003
- 2003-12-17 CN CNB2003801070872A patent/CN100415217C/en not_active Expired - Fee Related
- 2003-12-17 CN CNA2008101361548A patent/CN101310724A/en active Pending
- 2003-12-17 BR BR0317436-0A patent/BR0317436A/en not_active IP Right Cessation
- 2003-12-17 EP EP03818838A patent/EP1578409B1/en not_active Expired - Lifetime
- 2003-12-17 US US10/738,906 patent/US7414058B2/en not_active Expired - Fee Related
- 2003-12-17 JP JP2005510511A patent/JP2006514697A/en not_active Withdrawn
- 2003-12-17 WO PCT/US2003/040456 patent/WO2005044245A1/en active Application Filing
- 2003-12-17 NZ NZ540493A patent/NZ540493A/en not_active IP Right Cessation
- 2003-12-17 EP EP10186097A patent/EP2295047A3/en not_active Withdrawn
- 2003-12-17 TW TW092135740A patent/TWI331036B/en not_active IP Right Cessation
- 2003-12-17 MX MXPA05006790A patent/MXPA05006790A/en active IP Right Grant
- 2003-12-17 ES ES03818838T patent/ES2354875T3/en not_active Expired - Lifetime
- 2003-12-17 AT AT03818838T patent/ATE490775T1/en not_active IP Right Cessation
- 2003-12-17 EP EP10186087A patent/EP2269596A3/en not_active Withdrawn
- 2003-12-17 DE DE60335294T patent/DE60335294D1/en not_active Expired - Lifetime
- 2003-12-17 AU AU2003304527A patent/AU2003304527B2/en not_active Ceased
-
2005
- 2005-05-31 ZA ZA200504478A patent/ZA200504478B/en unknown
- 2005-07-18 NO NO20053509A patent/NO20053509L/en not_active Application Discontinuation
- 2005-09-28 HK HK05108564.4A patent/HK1074585A1/en not_active IP Right Cessation
-
2008
- 2008-07-29 US US12/181,736 patent/US20090029967A1/en not_active Abandoned
-
2010
- 2010-08-06 JP JP2010177518A patent/JP2011006431A/en active Pending
- 2010-08-31 AU AU2010214749A patent/AU2010214749B2/en not_active Ceased
-
2013
- 2013-01-29 JP JP2013013961A patent/JP2013136592A/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5565460A (en) * | 1993-07-27 | 1996-10-15 | Kyowa Hakko Koygo Co., Ltd. | Therapeutic purine agents for parkinson's disease |
US5933964A (en) * | 1996-07-17 | 1999-08-10 | Wahl Clipper Corporation | Cutter blade for hair clippers |
US6630475B2 (en) * | 2000-05-26 | 2003-10-07 | Schering Corporation | Adenosine A2a receptor antagonists |
US20030139395A1 (en) * | 2001-09-13 | 2003-07-24 | Schering Corporation | Combination of an adenosine A2a receptor antagonist and an antidepressant or anxiolytic |
US7414058B2 (en) * | 2002-12-19 | 2008-08-19 | Schering Corporation | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060128694A1 (en) * | 2002-12-19 | 2006-06-15 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
US20070053993A1 (en) * | 2005-02-04 | 2007-03-08 | Sitkovsky Michail V | Method to predict and prevent oxygen-induced inflammatory tissue injury |
US8455437B2 (en) * | 2005-02-04 | 2013-06-04 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Method to predict and prevent oxygen-induced inflammatory tissue injury |
US9676780B2 (en) | 2012-12-20 | 2017-06-13 | Merck Sharp & Dohme Corp. | Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties |
WO2014105664A1 (en) * | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Piperazine-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2014105666A1 (en) * | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
JP2016504363A (en) * | 2012-12-28 | 2016-02-12 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Heterobicyclo-substituted- [1,2,4] triazolo [1,5-C] quinazoline-5-amine compounds having A2A antagonist properties |
US9708347B2 (en) | 2012-12-28 | 2017-07-18 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties |
US10011615B2 (en) | 2012-12-28 | 2018-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties |
WO2018013951A1 (en) * | 2016-07-15 | 2018-01-18 | Northwestern University | Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias |
US11246871B2 (en) | 2016-07-15 | 2022-02-15 | Northwestern University | Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias |
Also Published As
Publication number | Publication date |
---|---|
EP2295047A3 (en) | 2011-05-18 |
EP2269596A2 (en) | 2011-01-05 |
DE60335294D1 (en) | 2011-01-20 |
MXPA05006790A (en) | 2005-09-08 |
NO20053509L (en) | 2005-09-16 |
ZA200504478B (en) | 2006-02-22 |
AU2003304527B2 (en) | 2010-09-09 |
EP2269596A3 (en) | 2011-09-14 |
JP2011006431A (en) | 2011-01-13 |
EP1578409A1 (en) | 2005-09-28 |
HK1074585A1 (en) | 2005-11-18 |
AU2010214749B2 (en) | 2011-06-09 |
ES2354875T3 (en) | 2011-03-18 |
WO2005044245A1 (en) | 2005-05-19 |
CN1728990A (en) | 2006-02-01 |
US7414058B2 (en) | 2008-08-19 |
NO20053509D0 (en) | 2005-07-18 |
TWI331036B (en) | 2010-10-01 |
US20040138235A1 (en) | 2004-07-15 |
JP2013136592A (en) | 2013-07-11 |
BR0317436A (en) | 2005-11-16 |
AU2010214749A1 (en) | 2010-09-23 |
CN100415217C (en) | 2008-09-03 |
EP2295047A2 (en) | 2011-03-16 |
JP2006514697A (en) | 2006-05-11 |
NZ540493A (en) | 2008-04-30 |
TW200505927A (en) | 2005-02-16 |
AU2003304527A1 (en) | 2005-05-26 |
EP1578409B1 (en) | 2010-12-08 |
CN101310724A (en) | 2008-11-26 |
ATE490775T1 (en) | 2010-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7414058B2 (en) | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | |
US20060106040A1 (en) | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | |
US20110212972A1 (en) | Compositions and Methods for Treating Female Sexual Dysfunction | |
US20060128694A1 (en) | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | |
US10392390B2 (en) | 5-HT2C receptor agonists and compositions and methods of use | |
US20210214355A1 (en) | 5-ht2c receptor agonists and compositions and methods of use | |
CA2510655C (en) | Uses of adenosine a2a receptor antagonists | |
CA2710829A1 (en) | Uses of adenosine a2a receptor antagonists | |
MX2008004876A (en) | Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | |
WO2006024121A1 (en) | Use of n-phenylpiperazine derivatives and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |